Thank you to the 2014 ASHI Corporate Supporters

Abbott Molecular
Art Robbins Instruments
Bio-Rad Laboratories
Elsevier
GenDx
Histogenetics
Illumina
Immucor
Linkage Biosciences Inc.
MLC Group, LLC
National Marrow Donor Program
Olerup, Inc.
Omixon
One Lambda Inc., A Thermo Fisher Scientific Brand
Pacific Biosciences
STEMCELL Technologies Inc.
# Table of Contents

General Information ................................................. XX
ASHI Program Planning Committee ............................. XX
Abstract Reviewers .................................................... XX
Board of Directors .................................................... XX
Corporate Supporters .................................................. XX
Exhibitor Directory ................................................... XX
Award Winners ........................................................ XX
Schedule at a Glance .................................................. XX
Abstracts ............................................................... XX
Exhibit and Hotel Floor Plans ...................................... XX
General Information

REGISTRATION
Registration is located on the Plaza Building Concourse Level.

Monday, October 20   Noon – 7:00 PM
Tuesday, October 21   7:00 AM – 4:00 PM
Wednesday, October 22 7:30 AM – 6:00 PM
Thursday, October 23  8:00 AM – 4:00 PM
Friday, October 24    7:30 AM – 10:30 AM

SPEAKER READY ROOM
The Speaker Ready Room is located in Client Office 1 on the Plaza Building Concourse Level.

Monday, October 20   5:00 PM – 7:00 PM
Tuesday, October 21   7:00 AM – 4:00 PM
Wednesday, October 22 7:00 AM – 4:30 PM
Thursday, October 23   7:00 AM – 4:30 PM
Friday, October 24    7:30 AM – 10:30 AM

EXHIBITS/ INTERNET CAFÉ
Exhibits and the Internet café are located in the Plaza Exhibit Hall on the Plaza Building Concourse Level.

HOURS AND POSTER VIEWING

Monday, October 20   8:00 PM – 10:00 PM
Tuesday, October 21  10:00 AM – Noon
                     2:00 PM – 7:00 PM
Wednesday, October 22 10:30 AM – Noon
                       2:30 PM – 5:30 PM
Thursday, October 23  10:30 AM – Noon

POSTER MOUNTING TIMES:

Monday, October 20   3:00 PM – 7:30 PM
*all posters should be mounted by 7:30 PM on Monday, October 20. If additional time is needed please visit the registration desk.

POSTER DISMOUNTING TIME:

Thursday, October 23   Noon – 2:00 PM
(Any poster still in place at 2:00 PM will be discarded)
ADA COMPLIANCE
ASHI fully complies with the legal requirements of the Americans with Disabilities Act. If any participant is in need of special accommodations, please notify the hotel and indicate the type of assistance needed. ASHI cannot ensure the availability of appropriate assistance without advance notice.

CAMERAS AND CELL PHONES
The recording or taking photographs during ASHI educational programming is prohibited. Any violation of this policy may result in the offender being removed from the meeting. As a courtesy to fellow attendees, please turn off cell phones during educational sessions.

MEETING OBJECTIVES
The 40th ASHI Annual Meeting will provide participants with comprehensive state-of-the-art updates and glimpses into the future on a variety of topics related to the fields of genomics, immunogenetics, immunology, histocompatibility and transplantation. The keynote address will set the stage with a discussion of medical applications of the new supercomputers like “Watson” - a lot has happened since that computer first learned to play Jeopardy and beat the best of the best champions. Plenary and symposium sessions will then update participants on the ever-increasing knowledge of the role of HLA molecules as risk or protection factors for HIV, influenza, drug and pollen allergies, malaria and narcolepsy; on new ways of using typing for HLA and immune system genes for matching and for understanding human population history; and, on exciting new approaches to getting more people transplanted. A joint AABB Symposium will also enlighten participants about how ABO types affect transplantation.

Workshop sessions will provide participants with practical information that can be utilized right now in their laboratories and transplant programs. In 2014 these sessions will include clinically important updates on new UNOS/OPTN policies for kidney allocation and paired donor exchanges, and an ethics debate on paid organ donation. There will also be updates on using KIR, epitope websites and C1Q antibody binding tests for HPC or organ donor selection and updates on methods for clinically useful statistical calculations and for analyzing results from the latest types of next generation sequencing assays. Case studies in solid organ and stem cell transplantation provide attendees with informative presentations about specific challenges that laboratories have faced in providing testing for complex patients.

In addition, abstract and poster sessions will provide attendees the opportunity to learn about important new clinical and basic research projects that could change future laboratory and clinical practice.

After attending this meeting, participants will be able to identify important roles for histocompatibility and immune system genes that reach beyond transplantation, new ways to expand opportunities for transplantation and current best practices for selecting donors for both hematopoietic stem cell and organ transplantation. They will also be able to more critically assess various aspects of laboratory testing, from detection of clinically relevant antibodies to the very latest methods for HLA typing and for analyzing test results.

EVALUATION
Participants must complete an evaluation in order to receive a certificate documenting credits earned for attending sessions. Sessions must be attended in their entirety. Partial credit is not available. Following the meeting, complete the evaluation and print your certificate by visiting http://2014.ashi-hla.org/ and clicking on the evaluation-specific icon. A username and password will be provided to you via e-mail upon the end of the meeting. Online meeting evaluations will be available from October 20 – December 19, 2014, after which time certificates will no longer be available.
PHYSICIANS
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Institute for the Advancement of Human Behavior (IAHB) and the American Society for Histocompatibility & Immunogenetics. The IAHB is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA STATEMENT
The IAHB designates this live activity for a maximum of 33 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CHT, CHS, ABHI DIPLOMATES
The American Board of Histocompatibility and Immunogenetics has approved the 40th Annual Meeting content for a maximum of 33.0 contact hours (4.0 contact hours for Inspectors’ Workshop and 29 contact hours for the conference) or 4.95 CECs (0.6 CECs for Inspector’s Workshop and 4.35 CECs for the conference) of continuing education hours for completing each module.

ABSTRACT AWARDS
The following awards will be presented to the highest ranked abstracts accepted for oral presentations: ASHI Scholars, International Scholar, Best Solid Organ Case Study and Best Stem Cell Case Study. Four posters will be awarded for the following: Most Innovative, Most Clinically Relevant, President’s Choice, and People’s Choice.

INTERNET CAFÉ – SUPPORTED BY ABBOTT MOLECULAR
Complimentary computer stations are provided to access the Internet. The Internet café is located in the Plaza Exhibit Hall. Use of these computers is limited to 15 minutes per session.
Hotel Information

LINK @ SHERATON
Located on Lobby Level
Complimentary computers, docking stations for laptops, and printers. Open 24 hours daily.

PENFIELD’S BUSINESS CENTER
Located around the corner from the hotel lobby

Hours:
Monday – Friday 7:00am – 7:00pm
Saturday and Sunday 8:00am – 4:00pm

RESTAURANTS

15|Fifty Restaurant
Relax and enjoy at the 15|Fifty Lounge, conveniently located next to the Link @ Sheraton. 15|Fifty Lounge features the Sheraton Social Hour from 5:00pm - 7:00pm Monday through Friday and is the ideal location to treat yourself to great wine and friendly conversation.

15|Fifty Lounge is open daily from 4:00pm - 10:00pm

16 Mix
Enjoy the scenery from 16Mix featuring an open-air patio located on the 16th Street Mall. Their team of mixologists will create you the perfect signature cocktail that compliments your style.
Pair your tasty blend with a Mile High Angus Burger or a delicious Seared Tuna Niscoise Salad.

Open daily from 3:00pm - 2:00am
Happy hour: Monday - Friday from 4:00pm - 6:00pm

Peet’s Coffee & Tea
Peet’s Coffee & Tea is the perfect place to jump start the day with a hot or cold beverage along with a quick snack or light lunch.
Enjoy their freshly brewed and blended coffee or assorted teas while savoring the taste of their home made fresh baked pastries.

Open daily from 6:00am – 4:00pm

Yard House
Yard House Denver is an upscale-casual eatery known for great food, classic rock music and 130 taps of imported, craft and specialty ales & lagers.

Hours:
Sunday - Thursday: 11:00am - 12:00am
Friday - Saturday: 11:00am - 1:00am
Happy hour: Monday – Friday from 3:00pm – 6:00pm
Program Planning Committee

**PROGRAM PLANNING CHAIR**
Marilyn Pollack, PhD, D(ABHI)
Children’s Hospital Oakland

**PLENARY AND SYMPOSIUM SESSIONS**
Patricia Campbell, MBChB, FRCP(UK), FRCP(C)
University of Alberta Hospitals

Howard Gebel, PhD, D(ABHI)
Emory University Hospital

John Gerlach, PhD, D(ABHI)
Michigan State University

Amy Hahn, PhD, D(ABHI)
Albany Medical College

Malek Kamoun, MD, PhD
University of Pennsylvania

Dimitri Monos, PhD
University of Pennsylvania /Children’s Hospital of Philadelphia

E. Victoria Turner, PhD, D(ABHI)
St. Jude Children’s Research Hospital

Christine Miller
University of Colorado / ClinImmune

**WORKSHOP CHAIRS**
Nebila Abdulwahab, MT(ASCP), CHT, CHS
Ohio State University Hospital

David Partlow, MS, MT, CHS
MD Anderson Cancer Center

**ABSTRACT CHAIRS**
Annette Jackson, PhD, D(ABHI)
Johns Hopkins University School of Medicine

Shalini Pereira, PhD, D(ABHI)
Scisco Genetics, Inc.

Daniel Ramon, PhD, D(ABHI), HCLD(ABB)
University of Michigan

Paul Norman, PhD
Stanford University School of Medicine

**CONTINUING MEDICAL EDUCATION**
**ACCREDITATION MANAGER**
Sheryl Morgan
Amedco Corporation
# Abstract Reviewers

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moheeb Al-Awwami, PhD, CHT, CHS</td>
<td>King Faisal Hospital Specialist Hospital &amp; Research Centre</td>
</tr>
<tr>
<td>Medhat Askar, MD, PhD, D(ABHI)</td>
<td>Allogen Laboratories</td>
</tr>
<tr>
<td>Fleur Aung, MD</td>
<td>University of Texas</td>
</tr>
<tr>
<td>Lee Ann Baxter-Lowe, PhD, D(ABHI)</td>
<td>University of California San Francisco</td>
</tr>
<tr>
<td>Nouredinne Berka, PhD, D(ABHI)</td>
<td>Calgary Laboratory Services</td>
</tr>
<tr>
<td>Maria Bettinotti, PhD, D(ABHI)</td>
<td>Quest Diagnostics Nichols Institute</td>
</tr>
<tr>
<td>Rainer Blaszczyk, MD, PhD</td>
<td>Hannover Medical School</td>
</tr>
<tr>
<td>Benita Book, CHT, CHS</td>
<td>Indiana University</td>
</tr>
<tr>
<td>Bob Bray, PhD, D(ABHI)</td>
<td>Emory University Hospital</td>
</tr>
<tr>
<td>Kevin Burns, MD, D(ABHI)</td>
<td>Blood Source</td>
</tr>
<tr>
<td>Patricia Campbell, MBChB, MRCP(UK), FRCP(C)</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>Michael J. Cecka, PhD, D(ABHI)</td>
<td>University of California Los Angeles</td>
</tr>
<tr>
<td>Adriana Colovai, PhD</td>
<td>Montefiore-Einstein Transplant Center</td>
</tr>
<tr>
<td>Deborah Crowe, PhD, D(ABHI)</td>
<td>DCI Laboratory</td>
</tr>
<tr>
<td>Steven DeGoey, BS, CHS</td>
<td>Mayo Clinic</td>
</tr>
<tr>
<td>Julio Delgado, MD, MS, D(ABHI)</td>
<td>University of Utah</td>
</tr>
<tr>
<td>Sara Dionne, PhD</td>
<td>Labs, Inc.</td>
</tr>
<tr>
<td>Nicholas DiPaola, PhD</td>
<td>Ohio State University Medical Center</td>
</tr>
<tr>
<td>Ronald Domen, MD</td>
<td>Penn State Milton S. Hershey Medical Center</td>
</tr>
<tr>
<td>Ilias Doxiadis, PhD</td>
<td>Leiden University Medical Center</td>
</tr>
<tr>
<td>Zeying Du, MD, PhD</td>
<td>University of Illinois At Chicago</td>
</tr>
<tr>
<td>Moe Erefaei, MD, PhD</td>
<td>Puget Sound Blood Center</td>
</tr>
<tr>
<td>Sujata Gaitonde, MD</td>
<td>University of Illinois At Chicago</td>
</tr>
<tr>
<td>Manish Gandhi, MD</td>
<td>Mayo Clinic</td>
</tr>
<tr>
<td>Howard Gebel, PhD, D(ABHI)</td>
<td>Emory University Hospital</td>
</tr>
<tr>
<td>Ketevan Gendzekhadze, PhD</td>
<td>City of Hope</td>
</tr>
<tr>
<td>Maria Gerbase-De Lima, MD, PhD</td>
<td>Federal University of San Paulo</td>
</tr>
<tr>
<td>David Gjertson, PhD</td>
<td>University of California Los Angeles</td>
</tr>
<tr>
<td>Clara Gorodezky, Dsc, PhD</td>
<td>InDRE, SSA</td>
</tr>
<tr>
<td>Amy Hahn, PhD, D(ABHI)</td>
<td>Albany Medical College</td>
</tr>
<tr>
<td>Gregory Hale, MD</td>
<td>All Children’s Hospital</td>
</tr>
<tr>
<td>Vera Hauptfeld-Dolejsek, PhD, D(ABHI)</td>
<td>University of Alabama at Birmingham</td>
</tr>
<tr>
<td>William Hildebrand, PhD, D(ABHI)</td>
<td>University of Oklahoma Health Science Center</td>
</tr>
<tr>
<td>Chak-Sum Ho, PhD</td>
<td>Gift of Life Michigan</td>
</tr>
</tbody>
</table>
Abstract Reviewers (CONTINUED)

Jill Hollenbach, PhD, MPH  
*University of California, San Francisco School of Medicine*

Susan Hsu, PhD  
*American Red Cross Blood Services Penn-Jersey Region*

Charlene Hubbell, BS, MT(ASCP), SBB  
*Health Science Center*

Annette Jackson, PhD  
*Johns Hopkins University School of Medicine*

Andres Jaramillo, PhD, HCLD(ABB)  
*Gift of Hope Organ & Tissue Network*

Malek Kamoun, MD, PhD  
*University of Pennsylvania*

Siva Kanangat, PhD  
*Rush University Medical Center*

Ronald Kerman, PhD  
*Baylor College of Medicine*

Pamela Kimball, PhD, HCLD  
*Medical College of Virginia*

William Klitz, PhD  
*University of California, School of Public Health*

Ellen Klohe, PhD, D(ABHI)  
*Inland Northwest Blood Center*

Janette Kwok, PhD  
*Queen Mary Hospital*

Chantal Lacelle, MD, PhD  
*UT Southwest Medical Center*

Chih-Hung Lai, PhD  
*Cedars-Sinai Medical Center*

Curt Lind, CHS  
*Children’s Hospital of Philadelphia, Immunogenetics Lab*

Robert Liwski, MD  
*Dahhouise University*

Andrew Lobashevsky, MD, PhD, D(ABHI)  
*Indiana University School of Medicine*

Steven Mack, BA, PhD  
*Childrens Hospital Oakland*

Martin Maiers, PhD  
*National Marrow Donor Program*

Gabriel Maine, PhD  
*William Beaumont Hospital*

Susana Marino, MD, PhD, D(ABHI)  
*University of Chicago Hospital Medical Center*

Steven Marsh, PhD  
*Anthony Nolan Research Institute*

James M. Mathew, PhD  
*Northern Virginia, Feinberg School of Medicine*

Narinder Mehra, PhD  
*All-India Institute of Medical Sciences*

Derek Middleton, DSc, PhD, FRC  
*Royal Liverpool University Hospital*

Joshua Miller, MD  
*Northwest University Feinberg School of Medicine*

Thalachallour Mohanakumar, PhD, D(ABHI)  
*Washington University School of Medicine*

Dimitri Monos, PhD  
*University of Pennsylvania, Children’s Hospital of Pennsylvania*

Omar Moussa, PhD  
*Medical University of South Carolina Pathology & Laboratory Medicine*

Cathi Murphey, PhD  
*Southwest Immunodiagnostics, Inc.*

Karen Nelson, PhD, D(ABHI)  
*Puget Sound Blood Center Innogenetics*

Allen Norin, PhD, D(ABHI)  
*SUNY Downstate Medical Center*

Paul Norman, PhD  
*Stanford University*

Carol Pancoska, PhD, D(ABHI)  
*Community Blood Services*
## Abstract Reviewers (CONTINUED)

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noemi Pereira, PhD</td>
<td>Universidade Federal do Paraná</td>
</tr>
<tr>
<td>E. Victoria Turner, PhD, D(ABHI)</td>
<td>St. Jude Children’s Research Hospital</td>
</tr>
<tr>
<td>George Vlad, PhD</td>
<td>Columbia University</td>
</tr>
<tr>
<td>Paul Warner, PhD, D(ABHI)</td>
<td>Puget Sound Blood Center</td>
</tr>
<tr>
<td>Qingyong Xu, PhD</td>
<td>Saskatoon Health Region &amp; University of Saskatchewan</td>
</tr>
<tr>
<td>Danny Youngs, BS, CHS</td>
<td>Puget Sound Blood Center</td>
</tr>
<tr>
<td>Andrea Zachary, PhD, D(ABHI)</td>
<td>Johns Hopkins University- Immunogenetics</td>
</tr>
<tr>
<td>Adriana Zeevi, PhD, D(ABHI)</td>
<td>University of Pittsburgh Medical Center</td>
</tr>
<tr>
<td>Aiwen Zhang, MD, PhD</td>
<td>Allogen Lab, Cleveland Clinic</td>
</tr>
<tr>
<td>Yizhou Zou, MD, PhD</td>
<td>Centre South University China</td>
</tr>
</tbody>
</table>
2014 Board of Directors

2014 EXECUTIVE COMMITTEE

President
John A. Gerlach, PhD, D(ABHI) (2014)
Michigan State University
B228 Life Science Building
East Lansing, MI 48824
Phone: (517) 432-3467
gerlach@msu.edu

Vice President of Operations
Judith E. Baker, CHS, I(ASCP) (2014)
Mdbaker4@tx.rr.com

Past President
Marilyn S. Pollack, PhD, D(ABHI) (2014)
University of Texas Health Science Center
Department of Pathology
7703 Floyd Curl Drive
San Antonio, TX 78229
Phone: (210) 567-5698 — Fax: (210) 358-0777
pollack@uthscsa.edu

President-Elect
Malek Kamoun, MD, PhD (2014)
University of Pennsylvania
3400 Spruce Street HUP
7.020 Founders Pavilion Department Pathology
Philadelphia, PA 19104
Phone: (215) 662-4022
malekkam@mail.med.upenn.edu

Secretary
David Kiger, CHS(ABHI) (2016)
Wake Forest University Health Sciences
145 Kimel Park Drive
Suite 250, General Surgery
Winston-Salem, NC 27103
Phone: (336) 716-1816 — Fax: (336) 774-7665
dkiger@wakehealth.edu

Treasurer
Elizabeth R. Trimble, MT(ASCP), CHS(ABHI) (2015)
Via Christi Regional Medical Center
#3653 929 N St Francis
HLA Laboratory
Wichita, KS 67214
Phone: (316) 268-5447
Elizabeth_Trimble@via-christi.org

2014 BOARD OF DIRECTORS

Patricia M. Campbell, MBChB, FRCP(C) (2016)
University of Alberta Hospitals
Dept. of Medicine 4B4.27 WMHSC
8440 112 St.
Edmonton, AB T6G 2B7
Canada
Phone: (780) 407-7579 — Fax: (780) 407-7930
patricia.campbell@albertahealthservices.ca

Michael D. Gautreaux, PhD, D(ABHI) (2016)
Wake Forest University Health Sciences
HLA/Immunogenetics Lab
145 Kimel Park Dr., Suite 250
Winston-Salem, NC 27103
Phone: (336) 716-4456 — Fax: (336) 774-7665
mgautrea@wakehealth.edu

Walter Herczyk, MT(ASCP), CHS (2014)
Gift of Life Michigan
3861 Research Park Drive
Ann Arbor, MI 48108-2217
Phone: (734) 922-1062
WHerczyk@giftoflifemichigan.org

Donna P. Lucas, MS, CHS(ABHI) (2014)
Johns Hopkins University
School of Medicine
2041 East Monument St
Baltimore, MD 21205
Phone: (410) 955-3600 — Fax: (410) 955-0959
dlucas@jhmi.edu

Lorita Rebellato-De Vente, PhD, MS, D(ABHI) (2014)
ECU Brody School of Medicine
600 Moye Boulevard, Room 7518
Department of Pathology & Laboratory Medicine
Brody Building Room 7590
Greenville, NC 27858
Phone: (252) 744-4986
rebellatol@ecu.edu

Dean Sylvaria, BS, CHS(ABHI) (2015)
Beth Israel Deaconess Medical Center
Histocompatibility Lab
One Deaconess Rd., WCC-210
Boston, MA 02115
Phone: (617) 754-3320 — Fax: (617) 754-3288
dsylvari@bidmc.harvard.edu
2014 Board of Directors

E. Victoria Turner, PhD, D(ABHI) (2014)
St. Jude Children’s Research Hospital
262 Danny Thomas Place
HLA Lab MS250
Memphis, TN 38105-2794
Phone: (901) 595-3468 — Fax: (901) 595-5231
vicky.turner@stjude.org

Cynthia Taves, PhD, D(ABHI) (2016)
Lab Corp
DNA Identity Testing
1440 York Court Extension
Burlington, NC 27215
Phone: (336) 436-7546 — Fax: (336) 436-7384
tavesc@labcorp.com

Dawn R. Wagenknecht, MS, CHS (2014)
St. Francis Hospital
1500 Albany Street, Room 1109
HLA Vascular-Biology Lab
Beech Grove, IN 46107
Phone: (317) 782-7187
Dawn.Wagenknecht@franciscanalliance.org
Corporate Supporters

**DIAMOND LEVEL**
One Lambda Inc., A Thermo Fisher Scientific Brand  
(Unrestricted Educational Grant)  
(Pocket Schedule at a Glance)  
(Final Program)

**PLATINUM LEVEL**
Abbott Molecular  
(Internet Café)

ImmuCor  
(Lanyards)

**GOLD LEVEL**
Histogenetics  
(Registration Bags)

**SILVER LEVEL**
GenDx  
(ASHI’s Run for a Life 5k Fun Run/Walk)  
(Mobile App)

Olerup, Inc.  
(Water Bottles)

**BRONZE LEVEL**
Bio-Rad Laboratories  
(Distinguished Scientist Award)

Elsevier  
(International Scholar Award)

Illumina  
(Scholar Award)

Linkage Biosciences, Inc.  
(Distinguished Service Award)

National Marrow Donor Program  
(Outstanding Technologist Award)

**FRIENDS OF ASHI**
Art Robbins Instruments  
(OTA Dinner)

MLC Group, LLC  
(Pacific Biosciences)
### Exhibitor Booth Numbers

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott Molecular</td>
<td>105</td>
</tr>
<tr>
<td>American Foundation for Donation &amp; Transplantation</td>
<td>401</td>
</tr>
<tr>
<td>Axis-Shield PoC</td>
<td>310</td>
</tr>
<tr>
<td>Bio-Rad Laboratories</td>
<td>104</td>
</tr>
<tr>
<td>CEDARLANE</td>
<td>108</td>
</tr>
<tr>
<td>chemagen from PerkinElmer, Inc.</td>
<td>405</td>
</tr>
<tr>
<td>Conexio Genomics</td>
<td>406</td>
</tr>
<tr>
<td>GenDx</td>
<td>505</td>
</tr>
<tr>
<td>GenTrak, Inc.</td>
<td>216</td>
</tr>
<tr>
<td>Histogenetics</td>
<td>313</td>
</tr>
<tr>
<td>Illumina</td>
<td>407</td>
</tr>
<tr>
<td>Immucor, Inc.</td>
<td>301</td>
</tr>
<tr>
<td>LabCorp</td>
<td>110</td>
</tr>
<tr>
<td>Labs, Inc.</td>
<td>113</td>
</tr>
<tr>
<td>Linkage Biosciences, Inc.</td>
<td>100</td>
</tr>
<tr>
<td>Miltenyi Biotec</td>
<td>312</td>
</tr>
<tr>
<td>mTilda</td>
<td>511</td>
</tr>
<tr>
<td>National Marrow Donor Program</td>
<td>116</td>
</tr>
<tr>
<td>Olerup, Inc.</td>
<td>101</td>
</tr>
<tr>
<td>Omixon</td>
<td>506</td>
</tr>
<tr>
<td>One Lambda, Inc., A Thermo Fisher Scientific Brand</td>
<td>201</td>
</tr>
<tr>
<td>Pacific Biosciences</td>
<td>307</td>
</tr>
<tr>
<td>Path-Tec</td>
<td>504</td>
</tr>
<tr>
<td>Promega Corporation</td>
<td>111</td>
</tr>
<tr>
<td>PROTRANS GmGH</td>
<td>408</td>
</tr>
<tr>
<td>QIAGEN</td>
<td>512</td>
</tr>
<tr>
<td>Scisco Genetics, Inc.</td>
<td>510</td>
</tr>
<tr>
<td>Solid Phase Immunoassays Website</td>
<td>210</td>
</tr>
<tr>
<td>STEMCELL Technologies Inc.</td>
<td>500</td>
</tr>
<tr>
<td>Streck</td>
<td>214</td>
</tr>
<tr>
<td>SystemLink, Inc.</td>
<td>411</td>
</tr>
<tr>
<td>Texas BioGene</td>
<td>213</td>
</tr>
<tr>
<td>Therapak</td>
<td>112</td>
</tr>
<tr>
<td>Transplant Genomics Inc.</td>
<td>501</td>
</tr>
<tr>
<td>Viracor-IBT Laboratories</td>
<td>211</td>
</tr>
</tbody>
</table>
## Exhibitor Company Descriptions

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Booth Number</th>
<th>Address</th>
<th>Phone</th>
<th>E-mail</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott Molecular</td>
<td>105</td>
<td>1300 East Touhy Avenue, Des Plaines, IL 60018</td>
<td>(224) 279-3405</td>
<td><a href="mailto:michael.steel@abbott.com">michael.steel@abbott.com</a></td>
<td><a href="http://www.abbottmolecular.com">www.abbottmolecular.com</a></td>
</tr>
</tbody>
</table>

Abbott Molecular is a leader in molecular diagnostics — the analysis of DNA and RNA at the molecular level. Abbott Molecular's tests can also detect subtle but key changes in patients' genes and chromosomes and have the potential to aid with early detection or diagnosis, can influence the selection of appropriate therapies, and may assist with monitoring of disease progression.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Booth Number</th>
<th>Address</th>
<th>Phone</th>
<th>E-mail</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Foundation for Donation &amp; Transplantation</td>
<td>405</td>
<td>8154 Forest Hill Avenue, Suite 3, Richmond, VA 23235</td>
<td>(804) 323-9893</td>
<td><a href="mailto:skinner@seopf.org">skinner@seopf.org</a></td>
<td><a href="http://www.amfdt.org">www.amfdt.org</a></td>
</tr>
</tbody>
</table>

The American Foundation for Donation & Transplantation, formerly SEOPF, is the continuation of the oldest transplantation and donation professional organization in the United States. AFDT's services include: educational courses for transplant professionals (Basic & Specialist Histocompatibility Courses), proficiency testing program, insurance for transplant professionals, procurement billing, travel awards and living kidney donor insurance program. 1-800-KIDNEY9.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Booth Number</th>
<th>Address</th>
<th>Phone</th>
<th>E-mail</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>Axis-Shield PoC</td>
<td>310</td>
<td>P.O. Box 6863 Rodelokka, Oslo, Norway N0504</td>
<td>(472) 405-6000</td>
<td><a href="mailto:bjorn.henriksen@axis-shield.com">bjorn.henriksen@axis-shield.com</a></td>
<td><a href="http://www.axis-shield-density-gradient-media.com">www.axis-shield-density-gradient-media.com</a></td>
</tr>
</tbody>
</table>

Axis-Shield will display a range of Density Gradient Media for the isolation of cells, organelles, subcellular membranes, macromolecules and viruses using centrifugation techniques.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Booth Number</th>
<th>Address</th>
<th>Phone</th>
<th>E-mail</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bio-Rad Laboratories</td>
<td>104</td>
<td>4000 Alfred Nobel Drive, Hercules, CA 94547</td>
<td>(510) 741-5773</td>
<td><a href="mailto:diagcs@bio-rad.com">diagcs@bio-rad.com</a></td>
<td><a href="http://www.bio-rad.com/diagnostics">www.bio-rad.com/diagnostics</a></td>
</tr>
</tbody>
</table>

Bio-Rad offers a complete line of industry standard HLA Serology Typing Trays (Lymphotype); Serological (Lymphoscreen) and ELISA-based (AbScreen/Abldent*) Antibody Diagnostics Systems; Molecular Typing Systems (SSO and SSP) with full automation platforms; Immune Monitoring, Infectious Disease and Traditional Blood Group Serology Products to meet your laboratory needs.

*Not available in US.
### Exhibitor Company Descriptions (CONTINUED)

#### CEDARLANE

<table>
<thead>
<tr>
<th>1210 Torrentine Street</th>
</tr>
</thead>
<tbody>
<tr>
<td>Burlington, NC 27215</td>
</tr>
<tr>
<td>Phone: (336) 513-5135</td>
</tr>
<tr>
<td>E-mail: <a href="mailto:eddie.johnson@cedarlanelabs.com">eddie.johnson@cedarlanelabs.com</a></td>
</tr>
<tr>
<td><a href="http://www.cedarlanelabs.com">www.cedarlanelabs.com</a></td>
</tr>
</tbody>
</table>

CEDARLANE is a leading distributor and manufacturer of high quality reagents to the transplant and research communities. We specialize in producing COMPLEMENT for tissue typing and bacteriocidal assays. Other manufactured products include Cedarlane’s Lympholyte® cell separation media and Antibodies including our B and T cell Positive Control Antisera and antibodies to complement components.

#### chemagen from PerkinElmer, Inc.

<table>
<thead>
<tr>
<th>710 Bridgeport Ave.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shelton, CT 06484</td>
</tr>
<tr>
<td>Phone: (800) 762-4000</td>
</tr>
<tr>
<td>E-mail: <a href="mailto:office.chemagen@perkinelmer.com">office.chemagen@perkinelmer.com</a></td>
</tr>
<tr>
<td><a href="http://www.chemagen.com">www.chemagen.com</a></td>
</tr>
</tbody>
</table>

Chemagen is a leading supplier of automation and reagents for fast and reliable magnetic bead based DNA and RNA extraction for sample volumes from 10 ul to 10 ml for blood, tissues, saliva, bacteria, food, PCR products. All functions can be performed on the one instrument. Advantages of this unique system are fast processing, unmatched sample volume range and robust chemistry.

#### Conexio Genomics

<table>
<thead>
<tr>
<th>P.O. Box 1294</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fremantle, Australia 6959</td>
</tr>
<tr>
<td>Phone: +61 45 904 4327</td>
</tr>
<tr>
<td>E-mail: <a href="mailto:laura@conexio-genomics.com">laura@conexio-genomics.com</a></td>
</tr>
<tr>
<td><a href="http://www.conexio-genomics.com">www.conexio-genomics.com</a></td>
</tr>
</tbody>
</table>

Conexio Genomics is a privately owned life sciences company, pioneering a wide range of HLA Typing products and sequence analysis/variant detection software for over a decade. With users and patients in mind, Conexio has established itself as a world leader with innovative products such as Gamma-Type™.

#### GenDx

<table>
<thead>
<tr>
<th>Yalelaan 48</th>
</tr>
</thead>
<tbody>
<tr>
<td>Utrecht 3521CM, Netherlands</td>
</tr>
<tr>
<td>Phone: +31 30 252 3799</td>
</tr>
<tr>
<td>E-mail: <a href="mailto:info@gendx.com">info@gendx.com</a></td>
</tr>
<tr>
<td><a href="http://www.gendx.com">www.gendx.com</a></td>
</tr>
</tbody>
</table>

GenDx develops and markets a comprehensive line of In Vitro Diagnostic (IVD) tests and services, analysis software and education. The company is a pioneer in the area of Sequencing-Based Typing (SBT) for transplantation. Now supporting HLA laboratories worldwide with Sanger and Next Generation Sequencing optimized workflows to get to true high resolution HLA typing. For more information please go to www.gendx.com or contact us at support@gendx.com.
<table>
<thead>
<tr>
<th>Exhibitor Company Descriptions (CONTINUED)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th><strong>GenTrak, Inc.</strong></th>
<th>216</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O. Box 1290</td>
<td></td>
</tr>
<tr>
<td>Liberty, NC 27298</td>
<td></td>
</tr>
<tr>
<td>Phone: (336) 622-5266</td>
<td></td>
</tr>
<tr>
<td>E-mail: <a href="mailto:sfpresearch@aol.com">sfpresearch@aol.com</a></td>
<td></td>
</tr>
<tr>
<td><a href="http://www.GenTrakinc.com">www.GenTrakinc.com</a></td>
<td></td>
</tr>
</tbody>
</table>

GenTrak, Inc. manufactures a quality line of classical HLA serology trays and Frozen Cell trays. HLA serology testing provides quick, cost effective results as well as useful information for molecular typing. When used in conjunction with molecular products, serological typing helps resolve ambiguities and null alleles. Please come see our new Texas BioGene Molecular products including SSP and SBT.

<table>
<thead>
<tr>
<th><strong>Histogenetics</strong></th>
<th>313</th>
</tr>
</thead>
<tbody>
<tr>
<td>300 Executive Boulevard</td>
<td></td>
</tr>
<tr>
<td>Ossining, NY 10562</td>
<td></td>
</tr>
<tr>
<td>Phone: (914) 762-0300</td>
<td></td>
</tr>
<tr>
<td>E-mail: <a href="mailto:nezih@histogenetics.com">nezih@histogenetics.com</a></td>
<td></td>
</tr>
<tr>
<td><a href="http://www.histogenetics.com">www.histogenetics.com</a></td>
<td></td>
</tr>
</tbody>
</table>

Histogenetics specializes in HLA, KIR, ABO-Rh Sequence based Typing services using NGS for blood stem cell transplants. With proprietary state-of-the-art facilities Histogenetics serves clients globally. Histogenetics provides fast high throughput high resolution molecular tissue typing services for registries, donor centers, cord blood banks, transplant centers and HLA laboratories at a very competitive price.

<table>
<thead>
<tr>
<th><strong>Illumina</strong></th>
<th>407</th>
</tr>
</thead>
<tbody>
<tr>
<td>5200 Illumina Way</td>
<td></td>
</tr>
<tr>
<td>San Diego, CA 92122</td>
<td></td>
</tr>
<tr>
<td>Phone: (585) 202-4500</td>
<td></td>
</tr>
<tr>
<td>E-mail: <a href="mailto:info@illumina.com">info@illumina.com</a></td>
<td></td>
</tr>
<tr>
<td><a href="http://www.illumina.com">www.illumina.com</a></td>
<td></td>
</tr>
</tbody>
</table>

Illumina provides innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics; paving the way for molecular medicine and ultimately transforming healthcare.

<table>
<thead>
<tr>
<th><strong>Immucor, Inc.</strong></th>
<th>301</th>
</tr>
</thead>
<tbody>
<tr>
<td>550 West Avenue</td>
<td></td>
</tr>
<tr>
<td>Stamford, CT 06902</td>
<td></td>
</tr>
<tr>
<td>Phone: (203) 328-9512</td>
<td></td>
</tr>
<tr>
<td>E-mail: <a href="mailto:kmiller@immucor.com">kmiller@immucor.com</a></td>
<td></td>
</tr>
<tr>
<td><a href="http://www.immucor.com">www.immucor.com</a></td>
<td></td>
</tr>
</tbody>
</table>

Immucor is a global provider of transfusion and transplantation diagnostics. Our transfusion products include a complete line of reagents and scalable automation for immunohematology. For transplant, we provide molecular and antibody-based assays for HLA compatibility between donors and recipients. Our molecular and specialty diagnostic assays provide advanced technology for compatibility, hemostasis and platelet antibody testing.
### LabCorp

1440 York Court  
Burlington, NC 27298  
Phone: (336) 436-7418  
E-mail: balbacd@labcorp.com  
www.labcorp.com

Laboratory Corporation of America® Holdings (LabCorp®) operates one of the nation’s most extensive clinical laboratory networks. LabCorp has one of the largest and most experienced HLA testing laboratories, providing comprehensive HLA analysis, KIR genotyping, anti-HLA antibody testing, crossmatch, Immuknow, and Chimerism analysis. LabCorp’s Specialty testing services are offered globally.

### Labs, Inc.

6933 S. Revere Parkway  
Centennial, CO 80112  
Phone: (303) 979-2500  
www.labs-inc.org

LABS, Inc. is a non-profit, mission-driven provider of donor eligibility testing for solid organ, tissue and human cells. We help ASHI members by providing 24/7/365 quality laboratory services that contribute to sound transplantation decisions and help improve clinical outcomes. With 30 years’ experience, LABS continues to look beyond the test result to help each member fulfill their mission to shape a brighter future for the transplantation community.

### Linkage Biosciences, Inc.

890 Dubuque Avenue  
South San Francisco, CA 94080  
Phone: (866) 575-8915  
E-mail: emitchell@linkagebio.com  
www.linkagebio.com

Real-Time PCR HLA Typing. LinkSeq™ is the fastest and easiest method available for HLA typing — no more gels or probing and washing. Less hands on time is required, and LinkSeq provides HLA Typing results, including DP, in under 90 minutes. LinkSeq – Accurate, Fast, Easy HLA Typing. For more information, please visit www.linkagebio.com.

### Miltenyi Biotec

6125 Cornerstone Court E  
San Diego CA 92121  
Phone: (858) 202-0700  
E-mail: lilam@miltenyibiotech.com  
www.miltenyibiotech.com

Miltenyi Biotec’s mission is to improve scientific understanding and medical progress. We provide products and services that advance biomedical research and cellular therapy. Honoring this mission drives our commitment to support the translation of basic research into therapy in the areas of immunology, cancer, neuroscience and stem cell biology. We innovate products that address sample preparation, separation of cells and their analysis, and that advance the concept of cellular therapy. “Researchers working for researchers” is our promise to provide pioneering products to our customers.
Exhibitor Company Descriptions (CONTINUED)

mTilda 511
5292 Lost Creek Road
Eagle Point, OR 97524
Phone: (541) 826-6581
E-mail: barbara@mtilda.com
www.mtilda.com

With over a decade of perfecting the user’s approach, this HLA management software offers unprecedented abilities for search, vendor integration, accuracy and ease of use. A remarkably robust and completely integrated approach that allows you to do more faster, better and more accurately. Stop by for a demo!

National Marrow Donor Program, Bioinformatics Research 116
3001 Broadway Street, NE
Minneapolis, MN 55407
Phone: (612) 460-4230
E-mail: mwright@nmdp.org
https://bioinformatics.bethematchclinical.org/

NMDP: Bioinformatics Research
We provide HLA expertise and services for international researchers, have the data and expertise you need, and are the scientists for the NMDP. Come along and see how we can help you.

Olerup, Inc. 101
901 S. Bolmar Street
Suite R
West Chester, PA 19382
Phone: (877) 653-7871
E-mail: info.us@olerup.com
www.olerup.com

Olerup is a life science company with a focus on transplantation that provides high quality products and services, in order to facilitate safe and effective bone marrow and solid organ transplants. Olerup is the global distributor of innovative molecular diagnostic products and services for transplantation: HLA typing (Olerup SSP® and SBT Resolver™) and for non-HLA antibody detection (XM-ONE®). Olerup’s product offerings are distributed through Olerup, Inc. (Americas) and Olerup GmbH (Rest of World).

Omixon 506
Petzval Suite 56
Budapest 1119, Hungary
Phone: +1 (617) 500-0790
E-mail: sales@omixon.com
www.omixon.com

Omixon is a global biotechnology company that commercializes disruptive innovations specializing in targeted applications for Next Generation Sequencing (NGS). The Omixon Holotype HLA™ product combines a targeted HLA Assay and the Omixon HLA Twin™ software to deliver the most accurate high-resolution HLA genotyping available. Omixon maintains an active grant-funded research program and assists scientists and clinicians to analyze the most challenging genomic regions including HLA, KIR and ABO.
### One Lambda, Inc., A Thermo Fisher Scientific Brand

21001 Kittridge Street  
Canoga Park, CA 91303  
Phone: (818) 702-0042  
E-mail: john.hart@thermofisher.com  
www.onelambda.com

One Lambda, Inc., is celebrating 30 years as the global leader in transplant diagnostics and continues to offer a broad range of products to support clinicians and laboratories in the management of transplant patients. In addition to donor specific antibody (DSA) assays, our line of monitoring products includes both complement and non-complement binding assays. Our typing portfolio includes products from serology to NGS. Visit the One Lambda booth to discover how we can help you improve the standard of care in your transplant programs.

### Pacific Biosciences

1380 Willow Rd.  
Menlo Park, CA 94025  
Phone: (650) 521-8000  
E-mail: wweise@pacificbiosciences.com  
www.pacb.com

The PacBio® RS II DNA Sequencing system from Pacific Biosciences is the only system available that can sequence full-length HLA gene alleles and reliably provide directly-phased HLA types without imputation due to its industry leading read lengths, accuracy, and fast turnaround time.

### Path-Tec

1333-A Belfast Avenue  
Columbus, GA 31904  
Phone: (706) 569-6368  
E-mail: kwebb@path-tec.com  
www.path-tec.com

Path-Tec is a leading provider of specimen management solutions that include kit design, production, distribution, tracking and software management systems. We understand the importance of specimen integrity so we work with laboratories to design kits that assist with proper specimen collection and protection, meet transportation regulations and include tools to track supplies and specimens.

### Promega Corporation

2800 Woods Hollow Road  
Madison, WI 53711  
Phone: (608) 298-4842  
E-mail: maryjo.martinson@promega.com  
www.promega.com

Promega Corporation is a leader in providing innovative solutions to life science, forensic, clinical research and molecular diagnostics markets. Our products consist of kits, reagents and automated platforms. The new Maxwell® RSC Instrument is compatible with the Quantus™ Fluorometer, enhancing your HLA laboratory workflow by providing integrated quantification of extracted nucleic acid. Stop by the Promega booth to learn more.
### PROTRANS GmGH

Ketschau 2  
Hockenheim, Germany 68766  
Phone: +49 620 529 2990  
E-mail: mail@protrans.info  
www.protrans.info  

PROTRANS is a company for research, development and production of Diagnostic Products for Organ- and Bone Marrow Transplantation, located in Germany, near Frankfurt and next to the University City of Heidelberg. [www.protrans.info](http://www.protrans.info)

### QIAGEN

19300 Germantown Road  
Germantown, MD 20874  
E-mail: ronda.keys@qiagen.com  
www.qiagen.com  

QIAGEN is the leading global provider of sample and assay technologies that are used to transform biological materials into valuable molecular information. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to four customer classes: Molecular Diagnostics, Academia, Applied Testing, and Pharma.

### Scisco Genetics, Inc.

1100 Fairview Avenue North  
Suite D4-100  
Seattle, WA 98109  
E-mail: info@sciscogenetics.com  
www.sciscogenetics.com  

Scisco Genetics is dedicated to providing laboratories with state-of-the-art sequencing technologies through an integrated genotyping system (IGS). Using our system, clinical laboratories – already driving the transformation to precision medicine – can accelerate the innovation process and prevent the technological and informational stagnation consequent from widespread outsourcing of clinical testing.

### Solid Phase Immunoassays Website

2041 East Monument Street  
Baltimore, MD 21205  
Phone: (410) 955-3600  
www.immunoassays.net  

Members of the Johns Hopkins Immunogenetics Laboratory have created a website for all things related to solid phase antibody immunoassays. The website was created in response to discussions at the 16th International Histocompatibility and Immunogenetics workshop. At [www.immunoassays.net](http://www.immunoassays.net), you can enter into discussions about test interpretation and troubleshooting. The site provides information on the latest assays, performance of different test lots, correlations between solid phase and cell based test results, and serum treatments. There is information on bead assays, flow cytometry and ELISA as well as links to relevant publications. Please visit the website and become a member at [www.immunoassays.net](http://www.immunoassays.net). You can become a site moderator and lead discussions.

**Match Program Update**  
Please visit our booth for information on the updated version of the match program for living donor transplants, now in worldwide use to help transplant centers manage their kidney exchange programs.
## Exhibitor Company Descriptions (CONTINUED)

### STEMCELL Technologies Inc.

570 West 7th Avenue  
Suite 400  
Vancouver, BC V5Z 1B3 Canada  
Phone: 1 (800) 667-0322  
E-mail: info@stemcell.com  
www.stemcell.com

STEMCELL Technologies provides fast and easy cell isolation solutions for HLA and chimerism analysis, facilitating high-volume sample processing and reliable results. EasySep™ and RosetteSep™ are fast, gentle on cells, and stable at room temperature. SepMate™ isolates PBMCs in just 15 minutes, and RoboSep™ fully automates cell isolation, saving technician time and eliminating cross-contamination.

### Streck

7002 S. 109th Street  
Omaha, NE 68128  
Phone: 1 (800) 843-0912  
E-mail: cvollbracht@streck.com  
www.streck.com

Streck's molecular products provide reliable performance as well as flexibility and efficiency. Innovative products include a thermal cycler that can perform PCR in as little as 17 minutes, PCR tubes that promote rapid amplification and economic reagent usage, and kits for resistance detection.

### SystemLink, Inc.

23475 Rock Haven Way  
Suite 140  
Dulles, VA 20166  
Phone: (703) 651-5706  
E-mail: mgunessever@systemlink-inc.com  
www.histotrac.com

Visit the SystemLink booth to learn about building a complete, customizable HLA laboratory management system to meet the needs of your laboratory. HistoTrac is a seamless system with flexible design, providing functionality to make data entry and data access quick and easy.

Of special interest:  
- Paired Kidney Exchange module  
- HistoTrac on the Web

See the HistoTrac software for yourself - in the exhibit hall or in your office.
Exhibitor Company Descriptions (CONTINUED)

**Texas BioGene**

635 Presidential Drive  
Richardson, TX 75081  
Phone: (972) 644-1888  
E-mail: willy@texasbiogene.com  
www.texasbiogene.com

Texas BioGene Inc. offer SSP kits for low to medium resolution typing and SBT kits containing both Generic and Group Specific Amplification (GSA) primers for high resolution sequencing. We also offer simple automation solutions for SSP, SSO, SBT and NGS preparation. Please come to visit our booth for more information.

**Therapak**

4305 Hamilton Mill Road  
Suite 200  
Buford, GA 30518  
Phone: (770) 614-2931  
E-mail: jriley@therapak.com  
www.therapak.com

Therapak provides a complete solution to manage inventory of kits and supplies for sample collection sites and transporting specimens back to your laboratory. Therapak’s capabilities include custom kit design, validation, distribution, sample tracking, client specific form printing, auto-replenishment and reporting. Each service and product is tailored to meet customer, regulatory and market requirements.

**Transplant Genomics Inc**

1501 Beacon Street  
#1903  
Brookline, MA 02446  
Phone: (608) 217-7978  
E-mail: courtney@transplantgenomics.com  
www.transplantgenomics.com

Transplant Genomics Inc. (TGI) is a molecular diagnostic company committed to working with the transplant community to improve organ transplant outcomes. TGI will deliver noninvasive serial monitoring tests that provide clinicians with clear, actionable information to optimize immunosuppression therapy, enhance patient care and improve graft survival.

**Viracor-IBT Laboratories**

1001 NW Technology Drive  
Lee’s Summit, MO 64086  
Phone: (816) 554-5171  
E-mail: info@viracoribt.com  
www.viracorIBT.com

With 30+ years of specialized expertise in infectious disease, immunology and allergy testing for immunocompromised patients, Viracor-IBT gets results faster, when it matters most. We are passionate about delivering value to our clients, never losing sight of the connection between the testing we perform and the patients we serve.
Paul I. Terasaki Clinical Science Award

The Paul I. Terasaki Clinical Science Award was established in 2003 to honor an individual, group, or institution in recognition of significant accomplishments and/or contributions to the fields of clinical transplantation, histocompatibility and immunogenetics. This award was made possible by a grant from the Paul I. Terasaki Foundation.

THE WINNER OF THE 2014 PAUL I. TERASAKI CLINICAL SCIENCE AWARD IS:

Robert A. Bray, PhD
Emory University Hospital

Robert A. Bray, PhD, is currently a Professor in the Department of Pathology and Laboratory Medicine, School of Medicine, at Emory University. He is also the Co-Director of the Histocompatibility & Molecular Immunogenetics Laboratory at Emory (1989-Current). Dr. Bray received his undergraduate degree (1977) from Indiana University, Bloomington, Indiana and graduate degree (Ph.D. – Immunology) from Indiana University School of Medicine in Indianapolis, Indiana (1985). He did a post-doctoral fellowship at Rush Medical Center in Chicago, Il. (1985-1987) and subsequently, he became an Assistant Professor in the Department of Immunology/Microbiology and Assistant Director of the Clinical Immunology Laboratory (1987-1989) at Rush Medical Center. In 1989 Dr. Bray moved to Atlanta and Emory University. Initially, he was an assistant professor, and co-director of the HLA laboratory with Dr. Glenn Rodey. Dr. Bray also established and directed the diagnostic flow cytometry facility at Emory University from 1990 to 1997. He was promoted to Professor in 2001. Dr Bray is a past President of ASHI and has served on several Committees within UNOS, SEOPF (now AFDT), ASHI, ABHI and the NMDP. Some selected examples are: Past chairman, Proficiency Testing Committee (SEOPF), ASHI/ARB Regional Commissioner, Member and former Chair, ABHI Laboratory Director’s Examination Committee, Past Chairman, ABHI Credentials Review Committee, Member and former Chair, NMDP Histocompatibility Committee, and former UNOS board member (as ASHI President). Dr. Bray is also currently serving as the UNOS Region 3 Histocompatibility representative and vice-chair of the Histocompatibility committee.
The Rose Payne Award

The Rose Payne Award was established in 1984 to honor a great scientist and to recognize her longstanding contributions to the field of immunogenetics. As a founding member of ASHI, Dr. Rose Payne was always willing to share her knowledge and assist others in their endeavors. For more than 30 years, Dr. Payne made significant contributions in areas related to HLA. The Rose Payne Award was established as a tangible recognition of the high regard in which she was held.

THE WINNER OF THE 2014 ROSE PAYNE AWARD IS:

John A. Hansen, MD
Fred Hutchinson Cancer Research Center
(Award Supported by STEMCELL Technologies, Inc.)

Dr. Hansen was born in Minneapolis, Minnesota and graduated from the University of Minnesota with a BA in Biological Sciences. He received an MD from Stanford University. During medical school his research elective involved the study of canine cardiac allografts in the Cardiovascular Surgery laboratory of Dr. Norman Shumway. To pursue further his interest in transplantation immunology, he chose a fifth year research elective to work in transplant immunology in the laboratory of Professor Leslie Brent, St Mary’s Hospital, London aimed at inducing specific tolerance to skin allografts in a murine model by administration of ALS following intravenous priming with cell membrane extracts.

After graduating from medical school, Dr. Hansen continued his clinical training in internal medicine at the University of Minnesota where major advances were underway in clinical bone marrow transplantation (BMT) led by the very charismatic and inspiring Immunologist Dr. Robert A. Good. Dr. Hansen joined Dr. Good’s group as research fellow and was soon recruited by Dr. Bo Dupont to his laboratory and studies aimed at understanding the genetics of BMT, and identifying HLA functional polymorphisms and haplotype structure of the HLA-D region. When Dr. Good and his team moved to Memorial Sloan Kettering Cancer Center (MSKCC) in 1972/73, Dr. Hansen followed drawn by the opportunity to help establish a new clinical BMT program and continue his research in the Dupont laboratory.

In 1977, Dr. Hansen was recruited by Dr. E. Donnell Thomas to the Fred Hutchinson Cancer Research Center (FHCRC) and Puget Sound Blood Center (PSBC) in Seattle as a member of the Bone Marrow Transplant (BMT) program and Director of the HLA laboratory. In 1979 Dr. Hansen led the Seattle team an effort to identify an HLA matched unrelated donor for an ALL patient therapy resistant disease who lacked an HLA identical sibling. The patient achieved complete donor cell chimerism after myeloablative BMT and had an uneventful recovery with no graft-versus-host disease; unfortunately leukemia eventually recurred after more than a year in remission. This seminal clinical breakthrough was published as a case report in the New England Journal of Medicine in 1980 and stimulated wide-spread interest in expanding the lifesaving potential of BMT to other patients lacking a matched related donor. To meet the need for HLA typed volunteer BMT donors, Dr. Hansen collaborated with Drs. Jeffery McCullough and Herb Perkins to apply for a grant from the Office of Naval Research to establish a network of donor centers, transplant centers and a coordinating center now known as the National Marrow Donor Program (NMDP). NMDP facilitated the first unrelated donor matching and BMT in 1986 and spectacular growth and medical benefit followed thereafter. Dr. Hansen served several years as a member of the NMDP Board of Directors and was also Board Chairman.

Dr. Hansen is currently a Member of FHCRC, Professor of Medicine, University of Washington, and an Attending Physician in the SCCA Hematopoietic Cell Transplant program Medical Director of the Seattle Cancer Care Alliance (SCCA) Clinical Immunogenetics Laboratory.

Addendum

During his medical school research training at Stanford, Dr. Hansen was often the courier of blood samples from cardiac allograft recipients to Dr. Rose Payne’s laboratory for DLA typing and alloantibody screening. He soon learned that Dr. Payne was very cordial, and also that she had a well-earned reputation for asking fellows and students critical but encouraging questions. He recalls looking forward to these encounters, sometimes challenging but always interesting.
ASHI Distinguished Scientist Award

The ASHI Distinguished Scientist Award was established in 2001 to honor a distinguished scientist who is an ASHI member. This individual must have contributed significantly to the field of immunogenetics and/or transplant immunobiology.

THE WINNER OF THE 2014 ASHI DISTINGUISHED SCIENTIST AWARD IS:

Prof. Dr. Clara Gorodezky

Fuente De La Acordada No. 9

(Award Supported by Bio-Rad Laboratories)

Professor Clara Gorodezky is the Head of The Department of Immunology and Immunogenetics of The Instituto de Diagnostico y Referencia Epidemiologícos of the General Direction of Epidemiology at The Secretary of Health in Mexico, since 1983. Her undergraduate training at the National Autonomous University of Mexico (UNAM) was in Pharmaco-Biological and Chemistry Sciences and her Masters and PhD degrees were on Immunology. Her first role was as an associate scientist at the Laboratory of Immunology of The Secretary of Health in Mexico City, where she pioneered the area of Histocompatibility in Mexico, together with her mentor, Prof. Mario Salazar Mallén. She published the first scientific worldwide papers on the diversity of Mexican Mestizo population and Mexican Nahua and Otomies in 1972 and was a world pioneer in HLA and disease with her publications on HLA and disease in lepromatous leprosy and autoimmune diseases in Mexicans in 1973.

Clara was trained in Basic Techniques in Radioisotopes and Radiobiology at The Institute of Physics of UNAM & Nacional Institute of Nuclear Energy-INEN (1968); on Immunity of Infectious Diseases, WHO. Institute de Biochemié, Université du Lusanne, Switzerland (1974); she was a fellow in Histocompatibility with Prof. Jean Daussset at The Hôpital Saint Louis in Paris (1978) and with Dr. Paul Terasaki at The Immunogenetics Laboratory of The UCLA in Los Angeles, CA, in Workshop analysis data (1983). Here academic experience is enormous and has trained since 33 years ago many students for all the Latin-American Histocompatibility and Immunogenetic labs, helping them to get started with the available technology for the clinical purposes and research, having organized as a Director and Professor, The International Current Courses on Histocompatibility and Molecular Genetics sponsored by The American Society of Histocompatibility and Immunogenetics, ASHI, UNAM and ABHI, since 1982. She became a Professor of Immunology of The Graduate Programs of Immunology and Microbiology at The National School of Biological Sciences of The National Polytechnic School in Mexico (IPN) since 1982 and Professor and Thesis Mentor of The Graduate Programs of Medical and Biomedical Sciences at The UNAM since 1986.

Clara has published 172 original articles in scientific journals, 69 Book Chapters and 10 books. She has mentored 52 PhD and MSc students and is a member of 11 International and 8 National Scientific Societies. She is a Member of The National Council of Research (SNI), since 1984; she got the maximum degree (Level 3). She is a Member of The Mexican Academy of Sciences (1984) and of The National Academy of Medicine (1994), who recommends to the Mexican Government the health politics and standards to be followed. Clara has given 698 invited talks and poster and oral presentations in different parts of The USA, Europe, Latina America, Asia, Australia & South-Africa.

She was awarded as an International Councilor for the International Histocompatibility Workshops in 1996 and has been actively participating, as well as chaired different components in the International Workshops since 1973, working on Molecular Anthropology and detecting polymorphisms in different; Mexican Mestizo populations along the Country, and identifying new alleles and migration patterns and studying the epidemiological impact of HLA genes, KIRs, cytokine SNP polymorphisms and mHA in different Mexican Indian groups as well. She pioneered the studies on the association mechanisms of Type I Diabetes in Latin American groups and showed the contribution of DRB1 locus in this disease expression. She has received multiple national and International Awards. She serves as a reviewer and on Editorial boards of Human Immunology, Tissue Antigens, Immunology,
Immunological Methods, Immunity, Leukemia Research, Human Biology & Genes & Immunity. She co-founded the Latin American Society of Histocompatibility & organized one of the Latin American Workshops in Mexico City as well as a Symposium on Molecular anthropology, at The National Museum of Anthropology, and organized The International Summer School (2005), among other important academic international activities.

Clara became an ASHI member in 1980 and has served since then several Committees: She served as as the Chair of the International Affairs Committee for 10 years; she has participated in the Educational Committee since many years ago and has been part of the Faculty at the SEOPF Courses (1988-1994). Since 2001, she directs and organizes the International Symposia on Hematopoietic Stem Cell Transplantation, at the National Academy of Medicine, with the Academic Recognition and Educational Credits of the Division of Post-graduate Studies of the Faculty of Medicine, National University of Mexico-UNAM.

Most important is that Clara was a founder of The Fundación Comparte Vida A.C. (1998), a non-profit Organization, where she became the President of the Board since 2000. With this, she created and leads The Mexican Unrelated Bone Marrow Donor Registry- DONORMO in 1998 & The Altruistic Mexican Cord Blood Bank-BACEC in 2002, and started in Mexico the Program of BMT with unrelated donors. Among the several awards she has received, she got international grants from NIH and from the European Community for research studies in Immunogenetics of Cervical Cancer and on Molecular characterization of the Mexican groups. Finally, her contributions to the Public Health System in Mexico have been very valuable, with recommendations and discussions at The Forum For Installing, The Law Of Human Cloning In Mexico: (House of Representatives, 2002). At the House of Representatives, to establish the Mexican Law of Solid Organ Donation, 2003. Establishment of Standards and laws for HSC donation and for CB donation (the Senate); (2005, 2007, 2009 2012). Clara was an Invited Speaker, by the NIH, NCR, NSF, National Sciences and Engineering Research Council of Canada, CONACyT, Canadian Institutes of Health, European Commission, at the North American Gender Summit, 2013, Washington, to discuss “Researching sex effects in susceptibility to cancer”. At the National Academy of Medicine, The Superior Court of Justice of Mexico and the Mexican Association of the Pharmaceutical Industry, Clara was invited to assess Secretary of Health, on Challenges to universalize the Mexican Health System, 2014.

ASHI Distinguished Service Award

The ASHI Distinguished Service Award was established in 1999 to honor colleagues who have contributed significantly to serving ASHI.

THE WINNER OF THE 2014 DISTINGUISHED SERVICE AWARD IS:

Paul Warner, PhD, D(ABHI)
Puget Sound Blood Center
(Award Supported by Linkage Biosciences, Inc.)

Paul was born in Salmon, Idaho, and his family moved to Montana when he was a young boy. He received his Bachelor’s degree in Microbiology from Montana State University, and then went through Medical Technologist training in Spokane, Washington. Upon gaining board certification as a medical technologist, he started working as a technologist in the HLA lab at Inland Northwest Blood Center in Spokane, Washington, and immediately realized he had found a profession he would never leave. During the 14 years Paul worked at the INBC HLA lab, he went back to school part-time to get his Masters degree in biology, and spent a lot of his free time climbing, hiking, fishing and skiing in the Inland Pacific Northwest. In 1999, Paul was admitted to graduate school at Washington State University, and received his PhD in 2003. Paul then moved to Seattle to work at the Puget Sound Blood Center HLA lab, and became a credentialed HLA lab Director in 2007.
ASHI Outstanding Technologist Award

The Outstanding Technologist Award has honored some of the most active and creative technologists in the field of HLA. Candidates must have made significant and sustained contributions to ASHI. The Outstanding Technologist Award is dedicated to all ASHI technologists past, present and future for the fine work they do every day in creating better patient outcomes and saving lives.

THE WINNER OF THE 2014 OUTSTANDING TECHNOLOGIST AWARD IS:

Donna P. Lucas, MS, CHS
Johns Hopkins University
(Award Supported by National Marrow Donor Program)

Donna Lucas is currently the research manager for the Immunogenetics Laboratory at the Johns Hopkins University School of Medicine in Baltimore, MD. She received a BA from Wittenberg University in biology and a master’s degree in biotechnology from the Johns Hopkins University. She began her career in HLA in 1980 under the direction of Dr. Wilma Bias performing serum protein and red cell enzyme electrophoresis and MLCs. She then took a 7 year hiatus from histocompatibility working in the Johns Hopkins Neuromuscular research laboratory. She returned to the field in 1992 to work as a research tech for Dr. Mary S. Leffell who had been appointed as co-director to the Immunogenetics Laboratory along with Dr. Bias. Several years later Dr. Andrea Zachary joined the laboratory when Dr. Bias retired. Donna has continued to work for Drs. Zachary and Leffell since then overseeing research projects and aiding in the development and implementation of new technologies and methodologies in the laboratory.

With the support and encouragement of her laboratory directors Donna has been an active member of ASHI for more than twenty years and was accredited as a Certified Histocompatibility Specialist in 1996. She is currently serving on the organization’s board of directors and is a member of proficiency testing committee. Additionally she has served on the program planning committee, Accreditation Review Board and has served as an ASHI inspector for many years. Donna has supported both regional and national ASHI meetings as a moderator and speaker. She has contributed to the ASHI Lab Manual and coauthored more than 20 peer reviewed articles and chapters and 40 abstracts and posters.

Donna is a member of the Transplantation Society and AST and serves on the Examination Committee for the American Board of Histocompatibility and Immunogenetics.

Donna states that her career in HLA has been a wild ride with rarely a dull moment and has been honored to be part of ASHI and worked with such an exceptional group of people. She looks forward to working with new people and learning new things.
The ASHI Rising Star Award

The ASHI Rising Star Award (formerly the ASHI/AFDT J. Marilyn MacQueen Award) recognizes an outstanding HLA technologist who has worked in the field for fewer than three years and desires to pursue a career in HLA.

THE WINNER OF THE 2014 RISING STAR AWARD IS:

Alyson A. Morris, BS, CHT
Johns Hopkins University Immunogenetics Lab

Alyson Morris was born and raised in Baltimore, Maryland and earned a Bachelor of Science degree in Biology from High Point University in 2011. Following graduation, Alyson began a career in clinical histocompatibility and immunogenetics with the Johns Hopkins University Department of Medicine as an Immunogenetics Technologist. The Johns Hopkins Immunogenetics Laboratory is a notably recognized tissue typing lab and serves renal, thoracic, and bone marrow transplantation programs within the Johns Hopkins Comprehensive Transplant Center and the Inova Transplant Center.

Through this position Alyson gained experience in solid-phase immunoassays, flow cytometric and cytotoxic crossmatch tests, intermediate and high resolution HLA typing, and sample accessioning. Additionally, when the lab introduced new clinical assays for non-HLA antibodies, she was trained in flow cytometric crossmatch testing using endothelial cell precursors as targets and in ELISA testing for angiotensin II receptor type-1 (AT1R) antibody. Alyson also works cooperatively with supervisors, transplant coordinators, and surgeons while on call for the deceased donor program.

Shortly after obtaining her Histocompatibility Technologist certification from the American Board of Histocompatibility and Immunogenetics in September of 2012, Alyson began a research project exploring the role of C1q-activating donor-specific antibodies in renal transplantation recipients, concomitant with a rejection episode. With the assistance of her laboratory directors and supervisors, Alyson submitted an abstract to the ASHI 39th Annual Meeting in Chicago, IL that was accepted for an oral presentation in the Case Studies in Solid Organ Transplantation Workshop. Further, Alyson was a contributing author on two additional ASHI meeting abstracts submitted in 2013 and 2014, respectively.

Alyson has experienced both sides of transplantation, as her friend is a bone marrow transplant recipient and her aunt was a deceased organ donor. With her family, Alyson participates in the annual Dash for Organ and Tissue Donor Awareness sponsored by Gift of Life in Philadelphia. Through these experiences Alyson has become more connected to the field of histocompatibility and immunogenetics and has gained a unique perspective into transplantation.

Alyson is currently pursuing a Master of Science degree in Biotechnology at the Johns Hopkins University and hopes to continue to expand her role outside of the laboratory through training as a lab inspector and volunteering for an ASHI committee in the coming year. Alyson is appreciative of the opportunities afforded to her and extends her thanks to the Johns Hopkins Comprehensive Transplant Center and to the Johns Hopkins Immunogenetics Laboratory, as well as to her laboratory directors, supervisors, and coworkers for aiding in her development as a new HLA technologist.
ASHI Scholars and International Scholar Awards

The best abstracts submitted for the 2014 Annual Meeting will be recognized during the Awards Symposium and the submitters will give an oral presentation during the Special Abstract Scholar Session. These abstracts received the highest rating by the reviewers, and the awards are provided to recognize individuals who made a significant advance in either clinical or basic research areas. The authors were selected from more than 230 submitted abstracts. Recipients receive a monetary award and certificate of recognition for their research.

SPECIAL ABSTRACT SESSION: SCHOLAR AWARDS

Thursday, October 23 2:00 PM – 3:30 PM

**Neema Mayor, BSc (Hons), PhD - ASHI International Scholar**

*Anthony Nolan Research Institute*

*London, United Kingdom*

Abstract #59-OR: GENERATION OF 252 HLA CLASS I GENOMIC SEQUENCES IN A SINGLE SEQUENCING REACTION USING DNA BARCODES AND SINGLE MOLECULE REAL-TIME (SMRT) DNA SEQUENCING TECHNOLOGY

(Award Supported by Elsevier)

**E. Victoria Turner, PhD, D(ABHI) - ASHI Scholar**

*St. Jude Children’s Research Hospital*

*Memphis, TN*

Abstract # 56-OR: EFFECTS OF KIR 3DL1 AND HLA-Bw4 MISCLASSIFICATION ON DONOR SELECTION FOR NATURAL KILLER CELL THERAPY

(Award Supported by mTilda HLA Software Specialists)

**Curtis McMurtrey, PhD - ASHI Scholar**

*University of Oklahoma Health Sciences Center*

*Oklahoma City, OK*

Abstract #57-OR: DEEP LIGAND SEQUENCING REVEALS OVER 200 HLA-A*02:01 TOXOPLASMA GONDII LIGANDS

**Yi-Ping Jin, MD - ASHI Scholar**

*University of California Los Angeles*

*Los Angeles, CA*

Abstract #58-OR: PROTEIN TYROSINE KINASES SRC AND PI3K REGULATE HLA-II ANTIBODY-INDUCED SURVIVAL PROTEIN EXPRESSION IN ENDOTHELIAL CELLS
## Monday, October 20

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 am - 5:00 pm</td>
<td>GenDx User Group Meeting: SBT HLA Teaching Session</td>
<td>Director’s Row H</td>
</tr>
<tr>
<td>10:00 am - 1:00 pm</td>
<td>Omixon Biocomputing User Group Meeting: Novel Allele Discovery with Omixon HLA Twin™</td>
<td>Plaza Court 7</td>
</tr>
<tr>
<td>Noon – 4:00 PM</td>
<td>Accreditation Inspectors’ Training Workshop</td>
<td>Plaza C</td>
</tr>
<tr>
<td>Noon – 7:00 PM</td>
<td>Registration Open</td>
<td></td>
</tr>
<tr>
<td>5:00 PM – 7:00 PM</td>
<td>Accreditation, Standards, Proficiency Testing and Director Training and Review Program Updates</td>
<td>Plaza Ballroom ABC</td>
</tr>
<tr>
<td>7:00 PM – 8:00 PM</td>
<td>Keynote Address: When Sherlock Holmes Can’t Solve the Case - Watson to the Rescue!</td>
<td>Plaza Ballroom ABC</td>
</tr>
</tbody>
</table>

**Welcome**

*Marilyn S. Pollack, PhD, D(ABHI)*

**Introduction**

*John A. Gerlach, PhD, D(ABHI)*

*Murthy Devarakonda, PhD*

*IBM Thomas J. Watson Research Center*

---

## Tuesday, October 21

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM – 4:00 PM</td>
<td>Registration Open</td>
<td></td>
</tr>
<tr>
<td>8:00 AM – 9:30 AM</td>
<td>Plenary I: HLA and the Immunogenetics of Infectious Disease</td>
<td>Plaza Ballroom ABC</td>
</tr>
</tbody>
</table>

**HIV-1 and Dengue Virus Diversity, Immunogenetics and Vaccine Field Trials in Thai Populations**

*Henry Stephens, PhD, BSc (Hons)*

*University College London*

**HLA & Influenza**

*Paul Thomas, PhD*

*St. Jude Children’s Research Hospital*

**Moderators**

*David Eckels, PhD, D(ABHI)*

*Jill Hollenbach, PhD*
9:30 AM – 10:00 AM
AM Refreshment Break
Immucor Lounge is open

10:00 AM – Noon
Symposium I: The Role of HLA in Vaccines and Allergic Reactions
Plaza Ballroom ABC

HLA Restriction in Drug and Pollen Allergies
Bjoern Peters, PhD
La Jolla Institute for Allergy & Immunology

Influenza Vaccine Leading to Narcolepsy
Emmanuel Mignot, MD, PhD
Stanford University

An Overview of the Role of HLA on Vaccine Response
Gregory Poland, MD, MACP, FIDSA
Mayo Clinic and Foundation

Moderators
William Hildebrand, PhD, D(ABHI)
Neil Greenspan, MD, PhD

Noon – 2:00 PM
User Group Luncheons:
Overview of Illumina Technology & Applications
Governor’s Square 12

Linkage Biosciences, Inc.: Learn the Benefits of Real-Time PCR HLA Typing
Plaza D

One Lambda, Inc. A Thermo Fisher Scientific Brand: Bridges Between the Phenotype of Circulating Antibodies & the Phenotype of Antibody-mediated Injury in Solid Organ Transplants
Plaza EF

STEMCELL Technologies, Inc.: Tutorial
Governor’s Square 10

2:00 PM – 3:30 PM
Workshop 1: New UNOS Kidney Allocation and Paired Donor Exchange Policies
Plaza AB

Lee Ann Baxter-Lowe, PhD, D(ABHI)
Children’s Hospital of Los Angeles

Dolly Tyan, PhD, D(ABHI)
Stanford University

Moderator
Deborah Crowe, PhD, D(ABHI)
Workshop 2: Use of KIR in Donor Selection
Plaza C
Sarah Cooley, MD
University of Minnesota
E. Victoria Turner, PhD, D(ABHI)
St. Jude Children’s Research Hospital

Moderators
Jill Hollenbach, PhD
Paul Norman, PhD

Abstract Session 1: New & Improved NGS
Governor’s Square 14

Moderator
Daniel Geraghty, PhD

Abstract Session 2: Optimization of Histocompatibility Testing
Governor’s Square 15

Moderator
Nicholas DiPaola, PhD

3:30 PM – 4:00 PM
PM Refreshment Break
Immucor Lounge is open – complimentary beverages provided

4:00 PM – 5:30 PM
Workshop 3: From Research Abstract to Publication: Finding and Telling Your Story
Plaza C
Steven Mack, PhD, BA
Children’s Hospital Oakland
Thomas Annesley, PhD, DABCC, FACB
The University of Michigan

Moderator
David Partlow, MBA, MS

Workshop 4: The Ethics of Live Donation
Plaza AB
Igal Kam, MD
University of Colorado Denver
Gabriel Danovitch, MD
UCLA Division of Nephrology

Moderators
Brett Loehmann, CHT, CHS
Christine Miller

5:30 PM – 7:00 PM
Poster Session & Reception
Plaza Exhibit Hall/Foyer

7:00 PM – 9:00 PM
ASHI/ARB Inspectors’ & International Reception (by invitation only)
Governor’s Square 10 & Governor’s Foyer
Wednesday, October 22

7:30 AM – 6:00 PM  Registration Open

6:30 AM – 8:00 AM  Run for a Life 5K Fun Run/Walk (Shuttle to City Park at 6:15 AM)

8:30 AM – 10:00 AM  Plenary II: New Directions for the Characterization of the MHC
                      Plaza Ballroom ABC
                      
                      Generating Full-Length HLA Haplotypes
                      Paul Norman, PhD
                      Stanford University School of Medicine
                      
                      Typing Immune System Genes from SNP Array Data
                      Stephen Leslie, BSc Hons, DPhil
                      Murdoch Children’s Research Institute
                      
                      Moderators
                      Dimitri Monos, PhD
                      Marcelo Fernández-Viña, PhD, D(ABHI)

10:00 AM -10:30 AM  AM Refreshment Break
                      Immucor Lounge is open

10:30 AM – 12:30 PM  Symposium II: HLA and the Genome: From Ancestry to Identity
                      Plaza Ballroom ABC
                      
                      Mapping the Match: Genetic Ancestry and Self-Identification in 21st Century America
                      Jill Hollenbach, PhD
                      University of California San Francisco School of Medicine
                      
                      The Origin of Modern Humans Within Africa
                      Brenna Henn, PhD
                      Stony Brook University
                      
                      The Enigma of Easter Island: Evidence of an Early Contribution of Native Americans
                      Erik Thorsby, MD
                      Institute of Immunology
                      
                      Moderators
                      Derek Middleton, DSc, PhD, FRCPath
                      Henry Erlich, PhD

12:30 PM – 2:30 PM  User Group Luncheons:
                      Immucor, Inc.
                      Plaza F
                      Olerup Luncheon
                      Governor’s Square 12
                      One Lambda, Inc. A Thermo Fisher Scientific Brand: NXType™: A Solution to Next
                      Generation Sequencing HLA Typing
                      Plaza E
                      Pacific Biosciences Workshop: Advances in fully phased HLA & KIR typing
                      using SMRT® Sequencing
                      Plaza D
**2:30 PM – 4:00 PM**

**Workshop 5: HLA Typing by Next-Generation Sequencing - Targeted and Whole Genome Approaches**

Plaza AB

Robert Carter, PhD  
*St. Jude Children’s Research Hospital*

Curt Lind, CHS  
*Children’s Hospital of Philadelphia*

**Moderators**

Martin Maiers  
Dimitri Monos, PhD

**Workshop 6: Case Studies & More**

Plaza C

**Moderator**

Daniel Ramon, PhD

**Abstract Session 3: Role of HLA in Disease & Immunity**

Governor’s Square 14

**Moderator**

Brian Freed, PhD, D(ABHI)

**Abstract Session 4: Mechanisms of Tolerance & Rejection**

Governor’s Square 15

**Moderator**

Marcelo J. Pando Rigal, PhD, D(ABHI)

**4:00 PM – 4:30 PM**

**PM Refreshment Break**

Immucor Lounge is open - complimentary beverages provided

**4:30 PM – 6:00 PM**

**Workshop 7: Using Epitope Websites for Donor Selection**

Plaza AB

Rene Duquesnoy, PhD  
*University of Pittsburgh*

Illias Doxiadis, PhD  
*Leiden University Medical Center*

**Moderator**

Patrick Adams, MS, CHS(ABHI)

**Abstract Session 5: Best of the Rest**

Governor’s Square 14

**Moderator**

Howard M. Gebel, PhD, D(ABHI)

**Abstract Session 6: Genetic Diversity & Functional Polymorphisms**

Plaza C

**Moderator**

Marcel Tilanus, PhD
Abstract Session 7: Humoral Immunity & Transplantation
Governor’s Square 15

Moderator
Andrea Zachary, PhD, D(ABHI)

6:00 PM – 7:30 PM
Directors’ Forum
Plaza AB

Technologists’ Forum
Plaza C

Thursday, October 23

7:15 AM – 8:15 AM
Women in Transplantation Meeting
Governor’s Square 15

8:00 AM – 4:00 PM
Registration Open

8:30 AM – 10:00 AM
Plenary III: Scientific Award Lectures
Plaza Ballroom ABC

Rose Payne Awardee: Genomics of Hematopoietic Cell Transplantation. Donor Selection and Immune Monitoring
Paul Terasaki Awardee: Beads, Beliefs and the Blarney Stone
Distinguished Scientist Awardee: Epidemiological and Clinical Impact of HLA Polymorphisms in Different Mexican Populations

10:00 AM – 10:30 AM
AM Refreshment Break
Immucor Lounge is open

10:30 AM – Noon
Symposium III: Awards & Business Meeting
Plaza Ballroom ABC

Noon – 2:00 PM
User Group Luncheons:
Omixon Holotype HLA Luncheon
Governor’s Square 11
GenDx User Group Meeting: HLA Sequencing Based Typing Strategies: Sanger and NGS
Governor’s Square 15

2:00 PM – 3:30 PM
Joint AABB ASHI Symposium
Plaza AB

ABO Blood Group System Basics
Carol Pancoska, PhD, D(ABHI)
Einstein Medical Center

ABO Issues in Solid Organ Transplantation
Paul Warner, PhD, D(ABHI)
Puget Sound Blood Center
Schedule at a Glance (CONTINUED)

**ABO Issues in HSC and Cord Blood Transplantation**
Patricia Kopko, MD
*University of California, San Diego*

**Moderator**
Lesley Kresie, MD, D(ABHI)

Special Abstract Session: Scholar Awards
Plaza C

**Moderators**
Steven Marsh, PhD
Sarah Cooley, MD
Erik Thorsby, MD
Dimitri Monos, PhD

3:30 PM – 4:00 PM

**PM Refreshment Break**

4:00 PM – 5:30 PM

**Workshop 8: C1Q Pre-Transplant for Donor Selection**
Plaza AB
John Lunz, PhD
*University of Pittsburgh*
Thomas Ellis, PhD, D(ABHI)
*University of Wisconsin-Madison*

**Workshop 9: Understanding Common Statistical Methodologies for Histocompatibility and Immunogenetics Research**
Plaza C
David Gjertson, PhD
*University of California Los Angeles*
Dorry Segev, MD, PhD
*Johns Hopkins Outpatient Center*

8:00 PM – 11:00 PM

**ASHI Networking Dinner**
Lucky Strike
Ticketed Event

Friday, October 24

7:30 AM – 10:30 AM

**Registration Open**

8:00 AM – 10:00 AM

**Symposium IV: Panel Discussion – Effective Communication with Transplant Clinicians**
Plaza Ballroom ABC

**A Surgeon’s Perspective – Eliminating Obstacles to get More Transplants**
Robert Montgomery, MD, Dphil, FACS
*Johns Hopkins Medicine*

**A Surgeon’s Perspective - HLA Testing Needed for Tolerance Induction Protocols**
James Markmann, MD, PhD
*Massachusetts General Hospital*
A Nephrologist’s Perspective – The Need for Caution with DSA  
James Cooper, MD  
University of Colorado Hospital

A Lab Director’s/Nephrologist’s Perspective  
Patricia Campbell, MBChB, FRCP(UK), FRCP(C)  
University of Alberta Hospitals  
Moderator  
Malek Kamoun, MD, PhD

10:00 AM – 10:30 AM  
AM Refreshment Break

10:30 AM – Noon  
Plenary IV: Future Transplant Options – Getting More People Transplanted  
Plaza Ballroom ABC  

Novel Ways to Increase the Donor Pool  
Dorry Segev, MD, PhD  
Johns Hopkins Outpatient Center

Modulation of Antigen Presentation by Thymic Tissue Repopulation- Implications for Autoimmunity and Transplantation  
Massimo Trucco, MD  
Children’s Hospital of Pittsburgh

Hurdles to Bioengineering Human Lung for Clinical Use  
Joan Nichols, PhD  
University of Texas Medical Branch  
Moderators  
Annette Jackson, PhD  
Malek Kamoun, MD, PhD

Noon – 12:15 PM  
Meeting Adjournment

Future Annual Meetings  
Malek Kamoun, MD, PhD

2017 International Workshop  
Marcelo Fernández-Viña, PhD, D(ABHI)
Abstracts

Tuesday, October 21, 2014  2:00 PM - 3:30 PM

Abstract Session 1: New & Improved NGS

OR01
AUTOMATED ASSEMBLY OF COMPLEX IMMUNOGENETIC HAPLOTYPES USING LONG-READ SINGLE MOLECULE, REAL-TIME SEQUENCING OF FOSMIDS

Richard J. Hall1, Kevin Eng1, Lawrence Hon1, Chul-woo Pyo2, Daniel E. Geraghty2, Swati Ranade1. 1Pacific Biosciences, Menlo Park, CA; 2Fred Hutchinson Cancer Research, Seattle, WA


OR02
DEVELOPMENT OF ADVANCED NGS BASED HLA DNA TYPING METHOD: SS-SBT

Yuki Ozaki1, Shingo Suzuki1, Atsuko Shigenari1, Sayaka Ito1, Yuko Okudaira1, Anri Masuya1, Shigei Mitsunaga1, Masao Ota2, Hidetoshi Inoko1, Takashi Shiina1. 1Tokai University School of Medicine, Kanagawa, Japan; 2Shinshu University School of Medicine, Nagano, Japan

OR03
HLA-GENOTYPING OF CLINICAL SPECIMENS USING ION TORRENT-BASED NGS

Kathleen Davis1, Yuki Saito2, Jonathan Barone3, Erica S. Johnson1, Karl Beutner1, Wei Dong1, Chirayu Goswami1, Zixuan Wang4, Susan Hsu5. 1Thomas Jefferson University Hospital, Philadelphia, PA; 2Transplant Diagnostics/Thermo Fisher Scientific, Canoga Park, CA; 3American Red Cross, Philadelphia, PA; 4Thomas Jefferson University, Philadelphia, PA

K. Davis: Other (Identify); Company/Organization; Thermo Fisher, Free pre-market reagents. Y. Saito: Employee; Company/Organization; Thermo Fisher Scientific. J. Barone: Other (Identify); Company/Organization; Thermo Fisher Scientific, Free pre-market reagents. E. S. Johnson: Other (Identify); Company/Organization; Thermo Fisher, Free pre-market reagents. K. Beutner: Employee; Company/Organization; Thermo Fisher Scientific. W. Dong: Other (Identify); Company/Organization; Thermo Fisher Scientific, Free pre-market reagents. C. Goswami: Other (Identify); Company/Organization; Thermo Fisher, Free pre-market reagents. Z. Wang: Other (Identify); Company/Organization; Thermo Fisher, Free pre-market reagents. S. Hsu: Other (Identify); Company/Organization; Thermo Fisher Scientific, Free pre-market reagents.
Abstracts

**OR04**

**A MULTI-CENTER STUDY USING NEXT-GENERATION SEQUENCING (NGS) FOR HLA GENOTYPING**

Curt Lind¹, Deborah Ferriola¹, Anh Huynh¹, Jamie Duke¹, Anna Papazoglu¹, Medhat Askar², Attila Berces³, Mette Christiansen³, Wei Dong³, Manish Gandhi³, Tim Hague³, Gyorgy Horvath³, Susan Hsu⁵, Brad Johnson⁷, Malek Kamoun⁷, Jane Kearsn⁷, Raul Kooter⁸, Wietse Mulder⁸, Maarten Penning⁸, Erin Pierce⁷, Krisztina Rigo³, Erik Rozemuller⁷, Brittany Schneider⁸, Dawn Thomas², Dimitri Monos¹. ¹The Children’s Hospital of Philadelphia, Philadelphia, PA; ²Allogen Laboratories, Cleveland Clinic, Cleveland, OH; ³Omixon, Inc., Budapest, Hungary; ⁴Aarhus University Hospital, Aarhus, Denmark; ⁵American Red Cross - Penn-Jersey Blood Services Region, Philadelphia, PA; ⁶Mayo Clinic, Rochester, MN; ⁷University of Pennsylvania, Philadelphia, PA; ⁸GenDx, Utrecht, Netherlands


**OR05**

**COMPLETE RESEQUENCING OF EXTENDED GENOMIC REGIONS USING FOSMID TARGET CAPTURE AND SINGLE MOLECULE REAL-TIME (SMRT®) LONG READ SEQUENCING TECHNOLOGY**

Chul-woo Pyo¹, Cynthia Vierra-Green², Yoon Soo Pyon¹, Kevin Eng¹, Richard Hall¹, Lawrence Hon¹, Swati Ranade¹, Daniel Geraghty¹. ¹Fred Hutchinson Cancer Research Center, Seattle, WA; ²Center for International Blood and Marrow Transplant Research, Minneapolis, MN; ³Pacific Biosciences, Menlo Park, CA

**OR06**

**GROUP SPECIFIC, UNAMBIGUOUS FULL-LENGTH GENE HLA CLASS I TYPING BY SANGER SEQUENCING: A ROBUST SSBT STRATEGY FOR TYPING AND A GOLDEN REFERENCE FOR NEXT GENERATION SEQUENCING APPROACHES**

Mathijs Groeneweg, Fausto Palusci, Christel Meertens, Christien EM Voorter, Marcel GJ Tilanus. Maastricht University Medical Center, Maastricht, Netherlands

**LBOR01**

**ONE MILLION SAMPLES TYPED BY NGS - LESSONS LEARNED**

Vinzenz Lange¹, Irina Boehme¹, Patrick Paul¹, Johanna M. Andreas¹, Bianca Schoene¹, Philipp Quenzel¹, Kathrin Lang¹, Carmen Schwarzeit¹, Daniel M. Baier¹, Angela I. Lucaci-Timocek², Jan A. Hofmann³, Juergen Sauter³, Julia Pingel⁴, Alexander H. Schmidt⁵. ¹DKMS Life Science Lab, Dresden, Germany; ²DKMS German Bone Marrow Center, Tübingen, Germany
Abstract Session 2: Optimization of Histocompatibility Testing

**OR07**  
A NOVEL MULTIPLEX APPROACH TO DEFINE PERIPHERAL BLOOD HLA-SPECIFIC B-CELL SUBSETS IN CLINICAL TRANSPLANTATION  
Ahmed Akl, Anat Roitberg-Tambur, M. Javeed Ansari. Northwestern University, Chicago, IL

**OR08**  
IT’S ABOUT TIME. THE DEVELOPMENT OF THE RAPID OPTIMIZED SINGLE ANTIGEN BEAD (ROB) LABSCREEN® PROTOCOL TO EXPEDITE HLA ANTIBODY TESTING  
Robert Liwski1, Jorge Neumann2, Geoff Peladeau4, Kelly Heinstein4, Roxanne Sperry4, Robert Bray4, Howard Gebel4. 1Dalhousie University, Halifax, NS, Canada; 2Lab of Transplant Immunology, Porto Alegre, Brazil; 4Emory University, Atlanta, GA

**OR09**  
KEEP IT COOL. A NOVEL INHIBITOR COMPLEX EXCLUSION (ICE) PROTOCOL FOR LABSCREEN THAT PREVENTS THE “PROZONE” EFFECT  
Robert Liwski1, Robert Bray2, Howard Gebel2. 1Dalhousie University, Halifax, NS, Canada; 2Emory University, Atlanta, GA

**OR10**  
SUCCESSFUL USE OF VIRTUAL CROSSMATCH (VXM) IN DECEASED-DONOR RENAL TRANSPLANTATION (DDRT): A SINGLE CENTER EXPERIENCE  
Dessislava Kopchaliiska1, Sonika Puri2, Raja Rajalingam1, Stephen Tomlanovich2, John Roberts3. 1Immunogenetics and Transplantation Laboratory, San Francisco, CA; 2Department of Nephrology, San Francisco, CA; 3Department of Surgery, University of California San Francisco, San Francisco, CA

**OR11**  
THE IMPORTANCE OF SURROGATE CROSSMATCHING IN ASSIGNMENT OF HLD-DQ ANTIBODIES  
Aisha Eltayeb1, Patrick W. Adams1, Paula Steller2, Nicholas DiPaola3. 1Ohio State University, Columbus, OH; 2Ohio State University, Columbus, OH

**OR12**  
AUTOMATED FLOW CYTOMETRY CROSSMATCH USING THE BIOTEK ELx50 MICROPLATE WASHER  
David Freedom, Daniel Magas, Katarzyna Brooks, Bozena Labuda, Andres Jaramillo. Gift of Hope Organ & Tissue Donor Network, Itasca, IL
Abstracts

OR13
HIGH TITER ANTIBODY STRENGTH CANNOT RELIABLY BE DESCRIBED WITHOUT DILUTION
Jennifer Baye, Peggy Krefting, Laurie Krummel, Nancy Henrickson, Sigrid Johnson, Maurine Davidson, David Maurer. University of Minnesota Medical Center - Fairview, Minneapolis, MN

LBOR02
CROSSMATCH OPTIONS? CAN A CELL CAPTURE IMAGE BE WORTH A THOUSAND FLOW EVENTS?
Tom Franks1, Leo L. Chan2, Benjamin Paradis2, Brianna O’Donnell2, Daniel Ramon1. 1University of Michigan, Ann Arbor, MI; 2Nexcelom Bioscience LLC., St. Lawrence, MA

Wednesday, October 22, 2014 2:30 PM - 4:00 PM

Abstract Session 3: Role of HLA in Disease & Immunity

OR14
THE MACAQUE ALLELE MAMU-A1*004 IS FUNCTIONALLY SIMILAR TO HLA-B*57
Curtis McMurtrey1, Rico Buchli2, Ken Jackson1, Christopher Stewart1, Wilfried Bardet1, William Hildebrand1. 1University of Oklahoma HSC, Oklahoma City, OK; 2Pure Protein LLC, Austin, OK

C. McMurtrey: Consultant; Company/Organization; Pure Protein LLC. R. Buchli: Employee; Company/Organization; Pure Protein LLC. W. Hildebrand: Scientific/Medical Advisor; Company/Organization; Pure Protein LLC.

OR15
SUSCEPTIBLE HLA SHARED EPITOPES IN RHEUMATOID ARTHRITIS MEDIATE BINDING OF CITRULLINATED PEPTIDES TO THE MHC
Kirsten M. Anderson, Christina Roark, Michael Aubrey, Brian Freed. University of Colorado Denver, Aurora, CO

OR16
CHARACTERIZATION THE MAJOR AND MINOR LIGAND COMPARTMENT OF HLA-E
Curtis McMurtrey1, Wilfried Bardet1, Danijela Mojsilovic1, Ken Jackson1, Lauren Liles1, Fredda Schafer1, Melanie Harriff3, Gwendolyn Swarbrick3, Deborah Lewinsohn3, David Lewinsohn3, William Hildebrand3. 1University of Oklahoma HSC, Oklahoma City, OK; 3Oregon Health Science University, Portland, OR

OR17
THE EFFECT OF HLA EPITOPES ON COLLAGEN-SPECIFIC T CELL RESPONSES IN RHEUMATOID ARTHRITIS
Christina L. Roark1,2, Kirsten M. Anderson1, Michael T. Aubrey1, Brian M. Freed1,2, 1ClinImmune Labs, Aurora, CO; 2University of Colorado Anschutz Medical Campus, Aurora, CO; 3University of Colorado Anschutz Medical Campus, Aurora, CO
Abstracts

OR18
IMMUNOGENETIC BASIS OF TYPE 1 DIABETES IN THE INDIAN POPULATION
Narinder K. Mehra1, Neeraj Kumar1, Gurvinder Kaur1, Uma Kanga1, Nikhil Tandon2. 1All India Institute of Medical Sciences, New Delhi, India; 2All India Institute of Medical Sciences, New Delhi, India

OR19
FREQUENCY OF HLA-B*44:03-C*04:09N BEARING HAPLOTYPES AND PHENOTYPES IN LEUKEMIA PATIENTS
Brandt Moore, Edward Guerrero, Yudith Carmazzi, Kai Cao. UT MD Anderson Cancer Center, Houston, TX

OR20
THE MECHANISTIC DIFFERENCES IN HLA-ASSOCIATED DRUG HYPERSENSITIVITY
Heike Kunze-Schumacher, Huyton Trevor, Rainer Blasczyk, Christina Bade-Doeding. Hannover Medical School, Hannover, Germany

Wednesday, October 22, 2014 2:30 PM - 4:00 PM

Abstract Session 4: Mechanisms of Tolerance & Rejection

OR21
Gamma-delta T CELL EXPANSION ASSOCIATES WITH LESSER RISK OF ALLOANTIBODY DEVELOPMENT IN PEDIATRIC HEART TRANSPLANTATION

OR22
LIGATION OF HLA CLASS II MOLECULES BY HLA ANTIBODIES INDUCES ENDOTHELIAL CELL PERMEABILITY AND MONOCYTE TRANSENDOTHELIAL MIGRATION
Fang Li, Nicole Valenzuela, Xiaohai Zhang, Elaine F. Reed. University of California Los Angeles, Los Angeles, CA

OR23
THE INTEGRIN β4 CONNECTING SEGMENT DOMAIN IS REQUIRED FOR HLA CLASS I-MEDIATED ENDOTHELIAL CELL ACTIVATION
Nwe Nwe Soe, Xiaohai Zhang, Yiping Jin, Elaine F. Reed. UCLA, Los Angeles, CA
OR24
MONOCYTE RECRUITMENT TO HUMAN LEUKOCYTE ANTIGEN CLASS I ANTIBODY-ACTIVATED ENDOTHELIAL CELLS IS DEPENDENT UPON MTOR
Sahar Salehi, Nicole M. Valenzuela, Elaine F. Reed. UCLA, Los Angeles, CA
S. Salehi: Grant/Research Support; Company/Organization; NIH.

OR25
DYSREGULATION OF INNATE IMMUNE RESPONSES DUE TO PROMISCUOUS PEPTIDE REPERTOIRE OF HLA-E*01:01
Thomas Kraemer, Trevor Huyton, Heike Kunze-Schumacher, Wiebke Abels, Rainer Blasczyk, Christina Bade-Doeding. Hannover Medical School, Hannover, Germany

OR26
TOLEROCGENIC EFFECTS OF EVEROLIMUS AND OTHER DRUGS USED IN COMBINATION AS STUDIED USING THE “TREG-MLR”
James M. M. Mathew, Xuemei Huang, Joseph R. Leventhal, Lorenzo Gallon, Joshua Miller, Josh Levitsky. Northwestern University, Chicago, IL

LBOR03
ASSOCIATION BETWEEN CTL PRECURSOR FREQUENCY TO HLA-C MISMATCHES AND HLA-C ANTIGEN CELL SURFACE EXPRESSION
Moshe Israeli1, Dave L. Roelen1, Mary Carrington2, Effie W. Petersdorf3, Frans H. J. Claas1, Geert W. Haasnoot1, Machteild Oudshoorn1. 1Leiden University Medical Center, Leiden, Netherlands; 2Frederick National Laboratory for Cancer Research, Frederick, MD; 3Fred Hutchinson Cancer Research Center, Seattle, WA

OR27
ROLE OF AIRE GENE (AUTOIMMUNE REGULATOR) IN TRANSCRIPTIONAL AND POST-TRANSCRIPTIONAL REGULATION OF HLA-G
Breno L. Melo-Lima1,2, Isabelle Poras3, Fabricio C. Dias1, Philippe Moreau4, Eduardo A. Donadi1. 1School of Medicine of Ribeirao Preto, Ribeirao Preto, Brazil; 2Commissariat à l’Energie Atomique et aux Energies Alternatives, Paris, France
OR28
Bw4/Bw6 ON HLA-A AND HLA-C: THE FORGOTTEN SEROLOGICAL PROPERTIES OF HLA CLASS I ANTIGENS
Chak-Sum Ho¹, Daniel Ramon², Andrés Jaramillo³. ¹Gift of Life Michigan, Ann Arbor, MI; ²University of Michigan Medical School, Ann Arbor, MI; ³Gift of Hope Organ & Tissue Donor Network, Itasca, IL

OR29
DISCREPANT HLA-DQ EPITOPE EXPRESSION ON SINGLE ANTIGEN BEADS VERSUS B CELLS CARRYING THE SAME HLA-DQA1*/DQB1* ALLELES
Medhat Askar¹, Jane Kearns², Thanh-Mai Bui², Lynne Klingman¹, Aiwen Zhang¹, Malek Kamoun². ¹Cleveland Clinic, Cleveland, OH; ²University of Pennsylvania, Philadelphia, PA

OR30
ALEMTUZUMAB, BORTEZOMIB, AND INTRAVENOUS IMMUNOGLOBULIN PRE-TREATMENT REDUCES THE RISK OF ACUTE ANTIBODY MEDIATED REJECTION AFTER INTESTINAL TRANSPLANT IN HIGHLY SENSITIZED PATIENTS
Aiwen Zhang¹, Ajai Khanna², Gabriela Diaz³, Masato Fujiki³, Koji Hashimoto³, Lynne Klingman¹, Ana Bennett⁴, Kareem Abu-Elmagd⁵, Medhat Askar¹. ¹Allogen Laboratories, Cleveland Clinic, Cleveland, OH; ²Digestive Disease Institute, Cleveland Clinic, Cleveland, OH; ³Unidad de Inmunologia e Histocompatibilidad, Hospital Dr Carlos G. Durand, Buenos Aires, Argentina; ⁴Pathology and Lab Medicine, Cleveland Clinic, Cleveland, OH

OR31
SUCCESSFUL OUTCOMES OF COMBINED HEART LIVER TRANSPLANTS ACROSS PRE-FORMED HIGH LEVELS OF DONOR SPECIFIC HLA ANTIBODIES
Malek Kamoun¹, Jane Kearns¹, Maria Molina¹, Thanh-Mai Bui¹, Joyce Wald¹, Thomas Cappola², Lee Goldberg³. ¹University of Pennsylvania, Philadelphia, PA; ²Penn Transplant Center, Philadelphia, PA; ³University of Pennsylvania, Philadelphia, PA

OR32
CASE STUDY: DOA: DONOR ORIGINATING ANTIBODY; A CASE OF PASSIVE ANTIBODY TRANSFER
Sarah J. Rongione, Annette Jackson, Bethany L. Dale, Karl P. Schillinger, Paul Sikorski, Andrea A. Zachary. Johns Hopkins University, Baltimore, MD
OR33
GETTING OUT OF THE PANIC MODE: MATERNAL BLOOD CONTAMINATION IN A CORD BLOOD UNIT FOR DOUBLE CORD HEMATOPOIETIC CELL TRANSPLANTATION
Qi Wang, Chih-Hung Lai, Mehrnoush Naim, Geraldine Ong, Nancy L. Reinsmoen. Cedars-Sinai Medical Center, Los Angeles, CA

OR34
CLINICALLY USEFUL TOOL FOR COMPARING THEORETICAL AND EVIDENCE BASED HLA EPITOPES.
Erin Chang, Allen J. Norin. SUNY Downstate Medical Center, Brooklyn, NY

A.J. Norin: Speaker’s Bureau; Company/Organization; Immuncor - Lifecodes. Scientific/Medical Advisor; Company/Organization; ICON CL.

Wednesday, October 22, 2014 4:30 PM - 6:00 PM

Abstract Session 5: Best of the Rest

OR35
THE NEW OPTN KIDNEY ALLOCATION POLICY: INEQUITABLE ACCESS AMONG HIGHLY SENSITIZED PATIENTS
Robert Bray1, Patricia Brannon1, Charlene Breitenbach2, Tracy McRacken3, Monica Stephens3, Jennifer Lai4, Eddie Mui4, Howard Gebel1. 1Emory University, Atlanta, GA; 2Henrico Doctor’s Hospital, Richmond, VA; 3Sentara Norfolk General Hospital, Norfolk, VA; 4California Pacific Medical Center, San Francisco, CA

OR36
THE DYNAMICS OF SERUM FREE LIGHT CHAIN IMMUNOGLOBULINS AFTER KIDNEY TRANSPLANTATION
Thomas H.P.M. Habets1, Stefan J.J. Molenbroeck1, Jacqueline J.Y. Frijns1, Els Bielen1, Christina E.M. Voorter1, Gerard M.J. Bos1, Frank A.M. Redegeld2, Maarten H.L. Christiaans1, Marcel G.J. Tilanus1, Joris Vanderlocht1. 1Maastricht University Medical Center, Maastricht, Netherlands; 2Utrecht University, Utrecht, Netherlands

OR37
IMPACT OF PREEMPTIVE PERIOPERATIVE DESENSITIZATION ON DECEASED DONOR TRANSPLANTATION AND DSA ELIMINATION
Pam Kimball, Felecia McDougan. MCVH, Richmond, VA
Abstracts

OR38
INCREASED LEVELS OF CELL-FREE CIRCULATING DONOR DNA IN RECIPIENT DETECTED BY NEXT GENERATION SEQUENCING OF HLA AMPLECTONS: A POSSIBLE INDICATOR OF KIDNEY GRAFT REJECTION

Melinda V. Rastrou1, Yan Li1, Wei-min Liu2, Sunil M. Kurian2, Terri Gelbart2, Tony Mondala2, Michael M. Abecassis3, John Friedewald1, Daniel R. Salomon4, Henry A. Erlich1,2, Cherie L. Holcomb1. 1Roche Molecular Systems, Pleasanton, CA; 2The Scripps Research Institute, La Jolla, CA; 3Northwestern University, Chicago, IL; 4Children’s Hospital Oakland Research Institute, Oakland, CA

OR39
CARFIZOMIB FOR REFRACTORY ANTIBODY MEDIATED REJECTION IN LUNG TRANSPLANTATION THE IMPACT ON DSA


OR40
UTILITY OF ASSESSING THE C1Q BINDING ABILITY OF HLA ANTIBODIES IN MAXIMIZING DONOR POOLS AND PREDICTING RISK OF TRANSPLANT-RELATED MORBIDITY IN HEART TRANSPLANT

Hemant K. Parekh1, Joseph L. Rudic2, Phoebe W. Lai2, Justin Lin2, Phi A. Lai2, Steven S. Geier1. 1Temple University School of Medicine, Philadelphia, PA; 2Temple University Hospital, Philadelphia, PA

OR41
PLATELET CROSSMATCH VIA FLUORESCENCE CYTOMETRY: AN ALTERNATIVE APPROACH

Bobbie Rhodes-Clark, Soumya Pandey, Terry Harville. University of Arkansas for Medical Sciences, Little Rock, AR

T. Harville: Scientific/Medical Advisor; Company/Organization; Arkansas Regional Organ Recovery Agency, Baxter Biologics, CSL Behring, Grifols.
Wednesday, October 22, 2014

Abstract Session 6: Genetic Diversity & Functional Polymorphisms

**OR42**

**HLA-E POLYMORPHISM IN VIEW OF THE 1000 GENOMES PROJECT: A FULL LENGTH HLA-E SEQUENCING APPROACH REVEALS NEW AND NULL ALLELES**

Timo I. Olieslagers, Mathijs Groeneweg, Lotte Wieten, Christina EM Voorter, Marcel GJ Tilanus. Maastricht University Medical Center, Maastricht, Netherlands

**OR44**

**RNA AND PROTEIN EXPRESSION OF HLA-A*23:19Q**

Kevin E.H. Gerritsen1, Marie-Odile Joannis2, Lotte Wieten1, Birgit L.M.G. Senden-Gijsbers1, Frantz Agis2, Christina E.M. Voorter1, Marcel G.J. Tilanus1. 1University Hospital Maastricht, Maastricht, Netherlands; 2Centre Hospitalier Universitaire de Point-à-Pitre/Abymes, Point-à-Pitre, Guadeloupe; 3University Hospital Maastricht, Maastricht, Netherlands

**OR45**

**ANALYSIS OF THE EFFECT OF HLA-C EXPRESSION IN RENAL TRANSPLANT BIOPSIES THROUGH GENOTYPING A SINGLE NUCLEOTIDE POLYMORPHISM rs9264942T>C**

Peter Jindra1, Alida Hayner-Buchan2, Don Constantino3, David Conti4, Amy Hahn4. 1Baylor College of Medicine, Houston, TX; 2Albany Medical College, Albany, NY; 3Albany Medical College, Albany, NY; 4Albany Medical College, Albany, NY

**OR46**

**KIR ALLELE AND HAPLOTYPE DIVERSITY OF MAORI AND POLYNESIANS**

Neda Nemat-Gorgani1, Atan Edinur2, Jill A.ollenbach3, Paul P.J. Dunn4, Geoff K. Chambers2, Peter Parham1, Paul J. Norman1. 1Stanford University, Stanford, CA; 2Victoria University of Wellington, Wellington, New Zealand; 3Children’s Hospital Oakland Research Institute, Oakland, CA; 4New Zealand Blood Service, Epsom, New Zealand

**OR47**

**INTERLEUKIN-1 RECEPTOR (IL1-R): ROLE IN ANTI-CYTOMEGALOVIRUS (CMV) IMMUNE RESPONSE AND PROTECTION AGAINST CMV REACTIVATION AFTER ALLOGENEIC HEMATOPOETIC CELL TRANSPLANTATION**

Gaurav Tripathi1,2, Poonam D. Khan1, Rehan M. Faridi1, Victor Lewis1, Jan Storek1, Noureddine Berka1, Faisal M. Khan1,2,6. 1University of Calgary, Calgary, AB, Canada; 2University of Calgary, Calgary, AB, Canada; 3University of Calgary, Calgary, AB, Canada; 4Tom Baker Cancer Centre, Calgary, AB, Canada; 5Tissue Typing Laboratory, Calgary, AB, Canada; 6Calgary Laboratory Services, Calgary, AB, Canada

**OR48**

**DONOR AND RECIPIENT GENETIC POLYMORPHISMS AND DELAYED GRAFT FUNCTION IN KIDNEY TRANSPLANTATION**

Amador Goncalves-Primo1,2, Erika F. Campos1,2, Jose O. Medina-Pestana1,2, Hélio Tedesco-Silva1, Maria Gerbase-DeLima1,2. 1Associação Fundo de Incentivo à Pesquisa - AFIP, São Paulo, Brazil; 2Universidade Federal de São Paulo, São Paulo, Brazil; 3Hospital do Rim e Hipertensão, São Paulo, Brazil
Abstract Session 7: Humoral Immunity & Transplantation

OR49
INCIDENCE OF AT1R ANTIBODY IN LIVER TRANSPLANT CANDIDATES WITH FIBROSIS
Mary Carmelle Philogene, Naudia L. Jonassaint, Sabra Lewsey, Mary S. Leffell, Andrea A. Zachary. Johns Hopkins University, Baltimore, MD

OR50
RELEVANCE OF HLA ANTIBODY TITER COMPARED TO PRA AND ANTIBODY MFI WHEN TRYING TO IDENTIFY CLINICALLY RELEVANT UNACCEPTABLE ANTIGENS
Peter Jindra, Jerome Saltarrelli, Christine O’Mahony, Charles Van Buren, Eva McKissick, Noriel Acorda, Alfred Eaton, Nicholas Woolley, Phillip Erice, Angela Hoover, Clair Hollingsworth, John Chappelle, Ronald Kerman. Baylor College of Medicine, Houston, TX

OR51
ASSESSMENT OF THE LUMINEX® SINGLE ANTIGEN AND C1q ASSAYS’ ABILITY TO CORRELATE DONOR SPECIFIC ANTIBODIES WITH KIDNEY TRANSPLANT REJECTION
James C. Cicciarelli1,2, Nathan A. Lemp3, Michael Koss1,6, Rolando Montes3, Bruce Williams3, Noriyuki Kasahara1, Robert Naragh3,4, Tariq Shah5,5, Viracor-IBT Laboratories, Los Angeles, CA; 3Sharp Healthcare HLA Lab, San Diego, CA; 4USC Keck School of Medicine, Los Angeles, CA; 5St. Vincent Medical Center, Los Angeles, CA; 6Transplant Research Institute, Los Angeles, CA

OR52
IMMUNOGENICITY OF HLA-DRB3 AFTER KIDNEY TRANSPLANTATION AND THE DEVELOPMENT OF A TOOL FOR EPITOPE DISCOVERY USING MUTAGENIZED RECOMBINANT HLA-FUSION PROTEINS
Thomas H.P.M. Habets3, Evelien E. Bouwmans1, Jacqueline J.Y. Frijns1, Els Bielen1, Maarten H.L. Christiaans1, Sarah L. Morley5, Christina E.M. Voorter1, Joris Vanderlocht1, Marcel G.J. Tilanus1. 1Maastricht University Medical Center, Maastricht, Netherlands; 2University of Cambridge, Cambridge, United Kingdom

OR53
ANTIBODIES AGAINST PROTEASE-ACTIVATED RECEPTORS (PAR) AFTER IMMUNOSUPPRESSION WITHDRAWAL IN PEDIATRIC LIVING-DONOR LIVER TRANSPLANT
Michiko Taniguchi1, Ohe Hidenori2, Shinji Uemoto2, Kai Schulze-Forster3, Harald Heidecke4, Duska Dragun2, Gabriela Riemekasten1, Ralf Dechend1, Curtis Meaheara1, Judy Hopfield1, Paul I. Terasaki5, 1Terasaki Foundation, Los Angeles, CA; 2Kyoto University Hospital, Kyoto, Japan; 3CellTrend GmbH, Luckenwalde, Germany; 4Charité - Universitätsmedizin Berlin, Berlin, Germany

K. Schulze-Forster: Other (Identify); Company/Organization; CellTrend GmbH (owner). H. Heidecke: Other (Identify); Company/Organization; CellTrend GmbH (owner).
Abstracts

OR54
DE-NOVO DEVELOPMENT OF DONOR MISMATCHED HLA IS SIGNIFICANTLY REDUCED IN ABO-INCOMPATIBLE RENAL TRANSPLANT RECIPIENTS: IMPLICATION FOR LONG TERM ALLOGRAFT FUNCTION

Patricia Willey1, V. Subramanian1, M. Gunasekaran2, D. Phelan1, R. Delos Santos1, J. Wellen1, S. Shenoy1, T. Mohanakumar1,2.
1Barnes-Jewish Hospital, St. Louis, MO; 2Washington University School of Medicine, St. Louis, MO

OR55
HLA-EpiDB: A DATABASE FOR THE ANALYSIS OF HLA EPITOPE FREQUENCIES IN WORLDWIDE POPULATIONS

Faviel F. Gonzalez-Galarza1, Louise YC Takeshita2, Andrew R. Jones2, Derek Middleton1.
1Autonomous University of Coahuila, Torreon, Mexico; 2University of Liverpool, Liverpool, United Kingdom

Thursday, October 23, 2014 2:00 PM - 3:30 PM

Abstract Session 8: Scholar Awards

OR56
EFFECTS OF KIR 3DL1 AND HLA-Bw4 MISCLASSIFICATION ON DONOR SELECTION FOR NATURAL KILLER CELL THERAPY

E. Victoria Turner, Wing H. Leung. St. Jude Children’s Research Hospital, Memphis, TN


OR57
DEEP LIGAND SEQUENCING REVEALS OVER 200 HLA-A*02:01 TOXOPLASMA GONDII LIGANDS

Curtis McMurtrey1, Wilfried Bardet1, Ken Jackson1, Ira Blader1, William Hildebrand1. 1University of Oklahoma HSC, Oklahoma City, OK

C. McMurtrey: Consultant; Company/Organization; Pure Protein LLC. W. Hildebrand: Scientific/Medical Advisor; Company/Organization; Pure Protein LLC.

OR58
PROTEIN TYROSINE KINASES SRC AND PI3K REGULATE HLA-II ANTIBODY-INDUCED SURVIVAL PROTEIN EXPRESSION IN ENDOTHELIAL CELLS

Yi-Ping Jin, Elaine F. Reed. David Geffen School of Medicine, University of California Los Angeles, LOS ANGELES, CA
OR59

GENERATION OF 252 HLA CLASS I GENOMIC SEQUENCES IN A SINGLE SEQUENCING REACTION USING DNA BARCODES AND SINGLE MOLECULE REAL-TIME (SMRT) DNA SEQUENCING TECHNOLOGY

Neema P. Mayor1,2, James Robinson1,2, Swati Ranade3, Kevin Eng1, Shem Wallis-Jones1, Alasdair JM McWhinnie4, Will P. Bultitude1, William Midwinter1, Brett Bowman1, Lance Hepler1, Henny Braund1, J Alejandro Madrigal1,2, Katy Latham1, Steven GE Marsh1,2.

1Anthony Nolan, London, United Kingdom; 2UCL Cancer Institute, London, United Kingdom; 3Pacific Biosciences, Menlo Park, CA


P001

DSA SOLID-PHASE CROSSMATCHING DEMONSTRATES THAT PRONASE-TREATED B CELLS SOMETIMES FAIL TO BIND ANTI-CLASS I IgG

Patrick W. Adams, Aisha Eltayeb, Paula Steller, Nicholas DiPaola. Ohio State University, Columbus, OH

P002

CERNER PROVISION DOCUMENT IMAGING SOLUTION, MAXIMIZE THE HLA TYPING PROCESS EFFICIENCY

Fadi Al Zayer, Maha Al Harbi, Amal Al Gharably, Sahar Sandooqa, Moheeb Al-Awwami. King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

P003

TRANSLATING HLA DATA FROM THE LABORATORY TO THE ELECTRONIC MEDICAL RECORD, THE BUMPY ROAD OF EPIC IMPLEMENTATION

Laurine Maria Bow1, Jean Maatta1, Lizette Rosenthal2, Maria Stavropoulos1, George Manley1. 1Yale University School of Medicine, New Haven, CT; 2Yale New Haven Health System, Stratford, CT; 3SystemLink, Inc., Dulles, VA

G. Manley: Employee; Company/Organization; SystemLink.

P004

2014 XM-ONE PROFICIENCY TESTING (PT) PROGRAM UPDATE

Manuel R. Carreno1, Annette Jackson2, Bruno Vanherberghen1, Häkan Hall1. 1OLERUP, Inc, West Chester, PA; 2Johns Hopkins University, Baltimore, MD; 3Absorber, AB, Stockholm, Sweden

M.R. Carreno: Consultant; Company/Organization; OLERUP, Inc. B. Vanherberghen: Employee; Company/Organization; Absorber, AB. H. Hall: Employee; Company/Organization; Absorber, AB.
Abstracts

P005
LOW LEVEL ANTI-HLA ANTIBODIES: DETERMINING RELEVANT UNACCEPTABLE ANTIGENS BY SINGLE ANTIGEN MICROARRAY AND SPECIFIC /SURROGATE FLOW CROSSMATCHES

Robert Cirocco1, Kristin Gilbert2, Jennifer Mendiolina1, Lindsey Biondi2, Michael Moritz4. 1Lehigh Valley Health Network, Allentown, PA; 2Lehigh Valley Health Network, Allentown, PA; 3Lehigh Valley Health Network, Allentown, PA; 4Lehigh Valley Health Network, Allentown, PA

P006
SUCCESSFUL RENAL TRANSPLANTATION OF HIV+ PATIENTS WITH T CELL REACTIVE ANTIBODIES AND POSITIVE T CELL CROSSMATCH

Adriana I. Colovai1, Peter Masiakos1, Enver Akalin1, Liise Kayler1, Min Ling2. 1Montefiore Medical Center, Bronx, NY; 2UT Medical School at Houston, Houston, TX

P007
HIGHLY ACCURATE PREDICTION OF ALLELIC-RESOLUTION HLA TYPING BY HAPLOTYPE ANALYSIS OF LOW-RESOLUTION HLA TYPING

Zeying Du1, Andres Jaramillo2, Wuhua Sun1, Amishi Desai1, Stefan Vidovich1, Sujata Gaitonde1. 1University of Illinois At Chicago, Chicago, IL; 2Gift of Hope Organ & Tissue Donor Network, Itasca, IL

P008
AGGREGATED IgG CONTROL FOR PRONASE FC RECEPTOR (FcR) REMOVAL in FLOW CROSSMATCH

Steven S. Geier1, Phi A. Lai2, Justin Lin2, Phoebe W. Lai2, Joseph L. Rudic2, Hemant K. Parekh2. 1Temple University School of Medicine and Hospital, Philadelphia, PA; 2Temple University School of Medicine and Hospital, Philadelphia, PA

P009
REDUCING THE COST OF A ROSETTING METHOD WHICH IMPROVES FLOW CROSSMATCH SENSITIVITY BY REMOVING NEUTROPHILS AND MONOCYTES

Phi A. Lai, Hemant K. Parekh, Justin Lin, Phoebe Lai, Joseph Rudic, Steven S. Geier. Temple University School of Medicine and Hospital, Philadelphia, PA

P010
COMPARISON OF TREATMENTS OF THE SERUM FOR ELIMINATING INHIBITORY FACTORS IN THE LUMINEX SINGLE ANTIGEN ASSAY

Renato de Marco, Maria Gerbase-DeLima. Associação Fundo de Incentivo à Pesquisa - AFIP, São Paulo, Brazil

P011
MAKING THE MOST OF HLA SINGLE ANTIGEN ANTIBODY TESTING

Kelley MK Haarberg1, Nancy D. Herrera1, John J. Freidewald1, Joseph R. Leventhal1, Denis Glotz2, Anat R. Tambur1. 1Northwestern University, Chicago, IL; 2Hôpital Saint-Louis, Paris, France
Abstracts

P012
EVALUATION OF FOUR METHODS TO REDUCE BACKGROUND REACTIVITY AND INTERFERENCE IN SINGLE ANTIGEN BEAD ANTIBODY DETECTION
Erica Letwiniuk, Anne Halpin, Patricia Campbell, Luis Hidalgo. University of Alberta Hospital, Edmonton, AB, Canada

P013
ELEVATED BACKGROUND FLUORESCENCE IN SINGLE-ANTIGEN BEAD ANTI-HLA ANTIBODY ASSAYS IS NOT ASSOCIATED WITH A SPECIFIC AGE, GENDER, ETHNICITY, OR HLA TYPE
Izabelle Harville¹, Soumya Pandey², Bobbie Rhodes-Clark³, Terry Harville³. ¹LISA Academy, Little Rock, AR; ³University of Arkansas for Medical Sciences, Little Rock, AR
T. Harville: Scientific/Medical Advisor; Company/Organization; Arkansas Regional Organ Recovery Agency, Baxter Biologics, CSL Behring, Grifols.

P014
THE EFFECTS OF ANTIGEN TARGET NUMBER ON ACCURATE FCXM INTERPRETATION
Luis G. Hidalgo, Susan Hasenbank, Anne Halpin, Patricia M. Campbell. University Of Alberta, Edmonton, AB, Canada

P015
EVALUATION OF THE RELATIONSHIP BETWEEN PRE-TRANSPLANT EVALUATION OF DSA BY VARIOUS METHODS AND INCIDENCE OF AMR IN KIDNEY ALLOGRAFT RECIPIENTS
Eric K. Ho⁴, Lloyd E. Ratner⁴, David J. Cohen⁴, Lingzhi Li⁵, Xiwei Tang⁴, Raphael A. Clynes⁴, Nicole Suciu-Foca⁴, George Vlad⁴, E. Rodica Vasilescu¹. ¹Columbia University, New York, NY; ²Columbia University, New York, NY; ³Columbia University, New York, NY

P016
PRONASE TREATMENT OF T LYMPHOCYTES DECREASES CDC CROSSMATCH TESTING TIME BY 50% AND MAINTAINS DSA COMPLEMENT ACTIVATING SPECIFICITY
Anne Igboke, Jason Payne, Dana Crumback, Tammi Whitted, James Cicciarelli, Kevin Burns. BloodSource, Mather, CA

P017
HLA EXPRESSION DIFFERENCES ON B CELL SUBSETS ISOLATED FROM DECEASED DONOR TISSUE
June A. Jones, Melissa E. Jeresano, Charles Swisko, Annette M. Jackson. Johns Hopkins University, Baltimore, MD

P018
IDENTIFICATION OF UNACCEPTABLE HLA ANTIGENS WHEN PRESENT IN TRANSPLANT PATIENT SERA AT AN UNDILUTED OR NEAT TITER BUT NOT PRESENT AT A LOW TITER (≤ 1:16)
Peter Jindra, Jerome Saltarrelli, Christine O’Mahoney, Charles Van Buren, Eva McKissick, Noriel Acorda, Alfred Eaton, Nicholas Woolley, Phillip Erice, Angela Hoover, Clair Hollingsworth, John Chappelle, Ronald Kerman. Baylor College of Medicine, Houston, TX
Abstracts

P019
SENSITIZATION CHANGES ARE COMMON AND CLINICALLY RELEVANT IN WAITLISTED KIDNEY TRANSPLANT PATIENTS
James H. Lan, Michelle Hickey, Xiaohai Zhang, Elaine F. Reed, Qiuheng Zhang. UCLA Immunogenetics Center, Los Angeles, CA

P020
CAN LUMINEX DONOR SPECIFIC ANTIBODY CROSS MATCH BE A BETTER ALTERNATIVE OF COMPLEMENT DEPENDENT CYTOTOXICITY CROSS FOR RENAL TRANSPLANT CASES IN DEVELOPING COUNTRIES LIKE INDIA?
Ankit Mathur, Sanjana Dontula, Nutan Dighe, Latha Jagannathan Jagannathan. Rotary Bangalore TTK Blood Bank, Bangalore, India

P021
DTT CAN UNCOVER HIDDEN UAS
Jennifer Mendiolina, Robert Cirocco. Lehigh Valley Health Network, Allentown, PA

P022
FLOW CYTOMETRIC CROSSMATCH FOR DECEASED DONOR TRANSPLANT CANDIDATES USING SMALL NUMBER OF CELLS AND SERUM VOLUME IN MICROPLATE
Myoung Hee Park, Sohyun Kim, Hyewon Hwang, Heeseo Park, Jiye Kwak, Bok Nyun Han. Korea Organ Donation Agency, Seoul, Korea, Republic of

P023
TAGGING CELLS IN FLOW CYTOMETRY CROSSMATCH: PLATE METHOD PROVIDES HIGHER B CELL PERCENTAGE AS COMPARED TO TUBE METHOD
Prabhakar Putheti, Manikkam Suthanthiran, Vijay K. Sharma. The Rogosin Institute, New York, NY

P024
POTENTIAL FOR A FALSE POSITIVE B CELL FLOW CYTOMETRY CROSSMATCH WITH THE USE OF FLUORESCEN ISOTHYOCYANATE-GOAT-ANTI-HUMAN IMMUNOGLOBULIN-G ANTIBODY
Prabhakar Putheti, Rex Friedlander, Arvind Menon, Darshana Dadhania, Manikkam Suthanthiran, Vijay K. Sharma. The Rogosin Institute, New York, NY

P025
PRONASE TREATMENT OF SINGLE ANTIGEN BEADS (SAB) REAVEALS A COMPLEX BIOLOGY FOR EXPLAINING DENATURED HLA ANTIGENS
Tiffany K. Roberts, Gizem Tumer, Robert A. Bray, Howard M. Gebel. Emory University, Atlanta, GA
Abstracts

P026
A BIOTIN/STREPTAVIDIN ENHANCED SINGLE ANTIGEN BEAD (SAB) METHOD IMPROVES SENSITIVITY AND OVERCOMES COMPLEMENT MEDIATED INHIBITION
Tiffany K. Roberts1, Kathryn Tinckam2, Gizem Tumer1, Howard M. Gebel1, Robert A. Bray1. 1Emory University, Atlanta, GA; 2University of Toronto, Toronto, ON, Canada

P027
DONOR SPECIFIC HLA ANTIBODIES DETECTED BY LUMINEX CANNOT PREDICT THE OUTCOME OF A CDC OR FLOW CYTOMETRIC CROSSMATCH IN AN INDIVIDUAL PATIENT
Dave Roelen, Simone Brand-Schaaf, Sophia Stein, Frans Claas. Leiden University Medical Center, Leiden, Netherlands

P028
IMPROVING VIRTUAL CROSSMATCHES: USING TWO DIFFERENT CUTOFFS FOR RESOLUTION OF ANTI-DQ AND CLASS I/DR UNACCEPTABLE ANTIBODIES INCREASE ACCURACY IN PREDICTION OF FLOW CROSSMATCHES RESULTS
Alexandre Rouleau, Fernando Echeverry, Claude Daniel. INRS - Institut Armand Frappier, Laval, QC, Canada

P029
HLA-A, -B, -DRB1 ALLELE AND HAPLOTYPE FREQUENCIES IN RENAL TRANSPLANT CANDIDATES IN A POPULATION IN SOUTHERN BRAZIL
Patricia Keiko Saito1, Roger Haruki Yamakawa1, Erika Noda Noguti2, Gustavo Borelli Bedendo1, Waldir Veríssimo da Silva Junior1, Sergio Seiji Yamada1, Sueli Donizete Borelli1. 1State University of Maringa, Maringa, Brazil; 2Histogene Laboratory of Histocompatibility and Genetics, Maringa, Brazil

P030
THE EFFECTS OF HYPOTONIC DIALYSIS AND SPIN COLUMNS ON SERUM ANTI-HLA IgG LEVELS
Michael B. Solomon II, Matthew G. Fair, Angela Kessler, Jennifer Mendiolina, Robert Cirocco. Lehigh Valley Health Network, Allentown, PA

P031
NO MORE POOLED POSITIVE CONTROL SERUM: POSITIVE CONTROL SERUM FOR THE STANDARDIZATION OF HLA LABORATORY ASSAYS USING A COMBINATION OF CHIMERIC MONOClonAL ANTIBODIES AGAINST HLA AND AB NEGATIVE SERUM
Thomas Thompson, Sheree H. Waslaski, Douglas Gimlin, Cindi G. Marchman, Elise M. McPherson, Haywood Titchner, Carissa Lemerise, Cherryl Nasse, Karen A. Cellars, Omar Moussa. Medical University of South Carolina, Charleston, SC
**P032**  
**DSA IN THE ABSENCE OF KNOWN SENSITIZING EVENTS: WHAT TO DO?**  
Eric Wagner¹, Annie Mimeault¹, Serey-Phorn Sea¹, Isabelle Lapointe¹, Isabelle Côté², Sacha DeSerres³, Réal Noël², Isabelle Houde².  
¹CHU de Quebec-CHUL, Quebec, QC, Canada; ²CHU de Quebec-HDQ, Quebec, QC, Canada

**P033**  
**IMPACT OF CYP3A5 POLYMORPHISMS ON THE METABOLISM OF TACROLIMUS IN RENAL TRANSPLANT RECIPIENTS DURING A 4-YEAR FOLLOW-UP**  
Xuedong Wei¹, Mubin Sun¹, Yangyang Sun¹, Jun He¹, Jianquan Hou¹.  
¹The First Affiliated Hospital of Soochow University, Suzhou, China; ²The Third Affiliated Hospital of Soochow University, Changzhou, China; ³The First Affiliated Hospital of Soochow University, Suzhou, China

**P034**  
**TOWARDS STANDARDIZATION OF SOLID-PHASE ASSAYS**  
Tenisha West, Walter Herczyk, Sana Ramahi, Jerome Weidner, Susana R. Marino. University of Chicago Medicine, Chicago, IL

**P035**  
**PRONASE EFFECTS IN THE FLOW CYTOMETRY CROSSMATCH**  
Danny Youngs, Paul Warner. Puget Sound Blood Center, Seattle, WA

**P036**  
**C1Q SINGLE ANTIGEN BEAD ASSAY ONLY DETECTS HIGH TITER/AVIDITY CLASS-I ANTI-HLA ANTIBODIES DETECTED BY SINGLE ANTIGEN BEADS**  
Manish J. Gandhi, Steven DeGoey, Nicole Henderson, Laurie Voit, Justin Kreuter. Mayo Clinic, Rochester, MN  
*M.J. Gandhi: Consultant; Company/Organization; Thermo Fisher-One Lambda.*

**P037**  
**LACK OF C1Q REACTIVITY IN POST-LVAD PATIENT SERA**  
Peter Jindra¹, Jacek Pliszczynski¹, Charles Van Buren¹, Alfred Eaton¹, Nicholas Woolley¹, Jerome Saltarrelli², Eva McKissick¹, Noriel Acorda¹, Phillip Eric¹, Angela Hoover¹, Clair Hollingsworth¹, John Chappelle¹, Christine O’Mahony¹, O.H. Frazier², Hari Mallidi², Ronald Kerman¹.  
¹Baylor College of Medicine, Houston, TX; ²Baylor College of Medicine, Houston, TX

**P038**  
**USE OF HLA-ALLELE PAIRS WHICH DIFFER ONLY IN BW4/BW6 FOR ANTIBODY ANALYSIS**  
Maria Kafetz, Isabelle Wood, Edgar Milford, Indira Guleria. Brigham and Women’s Hospital, Boston, MA
P039
CORRELATION OF FLOW HLA ANTIBODY SCREENING AND LUMINEX SINGLE ANTIGEN BEAD ASSAY
Karine E. Lopes, Adella Clark, Liang Wan, Wendy E. Wegner, Dong-Feng Chen. Duke University Medical Center, Durham, NC

P040
THREE METHODS TO IDENTIFY CYTOTOXIC ANTIBODIES; ONE METHOD IS NOT ENOUGH
Mehrnoush R. Naim, Chih Hung Lai, Geraldine Ong, Qi Wang, Robin Masukawa, Maria Manalo, Alfredo Santiago, Dianne Paredes, Nancy L. Reinsmoen. Cedars Sinai Medical Center, Los Angeles, CA

P041
DONOR SPECIFIC ANTIBODY MEAN FLUORESCENCE INTENSITIES IN POSITIVE, NEGATIVE, AND EQUIVOCAL C4D RENAL TRANSPLANTS: IS EQUIVOCAL C4D A TIME FOR TREATMENT?
James C. Cicciarelli1, Michael Koss1,2, Tariq Shah3,4, Nathan A. Lemp1, Noriyuki Kasahara3, Robert Naraghi1,4. 1Viracor-IBT Laboratories, Los Angeles, CA; 2USC Keck School of Medicine, Los Angeles, CA; 3St. Vincent Medical Center, Los Angeles, CA; 4Transplant Research Institute, Los Angeles, CA

P042
PREVALENCE AND CLINICAL SIGNIFICANCE OF C1q BINDING DONOR SPECIFIC ANTIBODIES IN RENAL TRANSPLANTATION
Adriana Coloval1, Christina Savchik1, Summeye Calp Inal1, Peter Masakos1, Min Ling2, Liise Kayler1, Enver Akalin1. 1Montefiore Medical Center, Bronx, NY; 2UT Medical School at Houston, Bronx, NY

P043
ELEVATED EXPRESSION OF AIF-1 AND IL-18 AT EARLY KIDNEY TRANSPLANTATION MAY PREDICT ALLOGRAFT DYSFUNCTION BUT NOT THE DGF. NOVEL MARKERS OF PODOCYTES
D. Olga McDaniel, Joel Duff, Corey W. Sivils, Akshay Bangale, Jack Neill, Fauzia Butt, Christopher Anderson. University of MS Med Center, Jackson, MS

P044
C4d NEGATIVE ANTIBODY MEDIATED RENAL ALLOGRAFT REJECTION- NEED FOR MOLECULAR SIGNATURE
Michele Prod1, Maria Opperman1, Ina Kurbegovic-Skaljic1, Sylvia Piggott1, Erin Christian1, Nadia Parmakova1, David Cimbaluk1, Siva Kanangat1. 1Rush University Medical Center, Chicago, IL; 2Rush University Medical Center, Chicago, IL

P045
DONOR-SPECIFIC ANTIBODY CAN BE MITIGATED BY INCREASING ANTIMETABOLITE DOSING ALONE
H.C. Yang: Speaker's Bureau; Company/Organization; Novartis.
Abstracts

P046
DONOR SPECIFIC ANTIBODY TO TRANS-ENCODED DONOR HLA-DQ HETERO-DIMER
Dennis F. Habig1, Justine L. Gaspari1, Carrie L. Mowery1, Heather A. Casey1, Carolyn L. Fisher1, Margaret A. Maybach1, Jean A. Hess1, Kimberly J. Goss1, Zakiyah Kadry2, Nasr Ghahramani3, Riaz Ali Shah2, Ronald E. Domen1, Hiroko Shike1. 1Penn State Hershey Med Center, Hershey, PA; 2Penn State Hershey Med Center, Hershey, PA; 3Penn State Hershey Med Center, Hershey, PA.

P047
ANALYSIS OF EPITOPE SHARING AMONG HLA-A1,3,11 AND 80
Donna P. Lucas, Renato M. Vega, Andrea A. Zachary, Mary S. Leffell. The Johns Hopkins School of Medicine, Baltimore, MD.

P048
HIGH FREQUENCY OF HLA-DQ ANTIBODIES IN HEART TRANSPLANT PATIENTS
Melissa E. Jeresano1, Karl P. Schillinger1, Ryan J. Tedford2, Andrea A. Zachary1. 1Johns Hopkins University, Baltimore, MD; 2Johns Hopkins Medical Institutions, Baltimore, MD.

A.A. Zachary: Scientific/Medical Advisor; Company/Organization; Scientific Advisory Board Immucor.

P049
THE COMPLEXITY OF ANTI-HLA ANTIBODIES IN IMMUNOLOGICAL RESPONSE PATTERNS OF SENSITIZED TRANSPLANT PATIENTS
Rico Buchli1, Arend Mulder2, Annette Jackson3, Anat R. Tambar4, René J. Duquesnoy5, Rebecca D. McAdams1, Rick Eggers6, Georgina Lopez Padilla7, Daniel Zehnder7, David P. Lowe8, David C. Briggs9, Robert Higgins10, Frans H.J. Claas11, Mike Hogan6, William H. Hildebrand12. 1Pure Protein LLC, Oklahoma City, OK; 2Leiden University Medical Center, Leiden, Netherlands; 3Johns Hopkins University, Baltimore, MD; 4Feinberg School of Medicine, Northwestern University, Chicago, IL; 5University of Pittsburgh Medical Center, Pittsburgh, PA; 6GMSBiotech, Tucson, AZ; 7University Hospitals of Coventry & Warwickshire NHS Trust, Coventry, United Kingdom; 8Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; 9NHSBT Birmingham, Birmingham, United Kingdom; 10University Hospitals of Coventry & Warwickshire, Coventry, United Kingdom; 11Leiden University Medical Center, Leiden, Netherlands; 12Oklahoma University Health Sciences Center, Oklahoma City, OK.

P050
CORRELATION OF THE PRESENCE OF COMPLEMENT BINDING DE NOVO DSA AND PATHOLOGY DEFINED ANTIBODY MEDIATED REJECTION (pAMR) IN HEART RECIPIENTS
Chih-Hung Lai1, Geraldine Ong1, Mehrnoush Naim1, Qi Wang1, Mark Haas2, Jignesh Patel1, Jon Kobashigawa1, Nancy Reinsmoen1. 1Cedars-Sinai Med Ctr, Los Angeles, CA; 2Cedars-Sinai Med Ctr, Los Angeles, CA; 3Cedars-Sinai Med Ctr, Los Angeles, CA.

J. Kobashigawa: Grant/Research Support; Company/Organization; NIH. N. Reinsmoen: Grant/Research Support; Company/Organization; Thermo/Fisher.

P051
IDENTIFICATION OF NOVEL HLA ALLELES BY SEQUENCE BASED TYPING (SBT): A*33:73N AND C*03:218
Weicheng Zhao, Brandt Moore, Edward Guerrero, David Partlow, Kai Cao. UT MD Anderson Cancer Center, Houston, TX.
Abstracts

P052

HLA GENE MUTAGENESIS CAUSED BY TUMOR BLAST CELLS IN PERIPHERAL BLOOD

Weicheng Zhao, Edward Guerrero, Dana Willis, Kai Cao. UT MD Anderson Cancer Center, Houston, TX

P053

DISTRIBUTION OF KIR HLA LIGANDS IN TRANSPLANT PATIENTS AND THEIR CORD BLOOD UNIT (CBU) DONORS

Kai Cao1, Yudith Carmazzi1, Elizabeth Shpall1, Edward Guerrero1, Titus Barnes2, Brandt Moore1, Dana Willis1, Chitra Hosing1, Betul Oran1, Vinh T. Ngo1, Ana T. Artagas1, Tara Sadeghi1, Susan Armitage1, Marcelo Fernandez-Vina2, Katy Rezvani1. 1UT MD Anderson Cancer Center, Houston, TX; 2Stanford University School of Medicine, Palo Alto, CA

P054

GENOTYPING OF HLA NOVEL AND RARE ALLELES USING NEXT GENERATION SEQUENCING ON THE ION TORRENT PERSONNEL GENOME MACHINE (PGM), USING A NOVEL GROUP-SPECIFIC SANGER SEQUENCE BASED TYPING METHOD AS REFERENCE.

D. De Santis1, M. Groeneweg2, S. Doran1, I. Vukovic1, L. K. Smith1, S. J.J Molenbroeck2, F. Palusci2, C. E. Voorter2, M. G.J Tilanus2, P. Martinez1. 1PathWest, RPH, Perth, Australia; 2Maastricht University Medical Centre, Maastricht, Netherlands

P055

INS-VNTR POLYMORPHISM AND GENE EXPRESSION IN TYPE 1, TYPE 2 AND GESTATIONAL IN BRAZILIAN DIABETES MELLITUS PATIENTS

Flavia Porto Pela1, Adriane Feijó Evangelista2, Diane Rassi1, Maria Cristina Foss1, Milton Foss1, George Tadeu Nunes3, Celso Teixeira Mendes Junior1, Norma Lucena1, Eduardo A. Donadi1. 1FMRP-USP, Ribeirao Preto, Brazil; 2Hospital do Cancer de Barretos, Barretos, Brazil; 3Centro de Pesquisas Aggeu Magalhães, Recife, Brazil

P056

FREQUENCIES OF AUTOIMMUNE DISEASES ASSOCIATED POLYMORPHISMS IN MEXICAN POPULATION

Bernard Esquivel1, Martín Silva2. 1Total Quality Medicine, Mexico City, Mexico; 2Total Quality Medicine, Mexico City, Mexico

P057

INFLUENCE OF ACTIVATING AND INHIBITORY KILLER IMMUNOGLOBULIN-LIKE RECEPTOR GENES ON PREDISPOSITION TO LYMPHOCYTIC LEUKEMIAS

Rehan M. Faridi1, Taylor J. Kemp1, Poonam Dharmani-Khan1, Victor A. Lewis2, Jan Storek1, Noureddine Berka4, Faisal M. Khan4. 1The University of Calgary, Calgary, AB, Canada; 2Alberta Children’s Hospital, Calgary, AB, Canada; 3The University of Calgary, Calgary, AB, Canada; 4Calgary Laboratory Services, Calgary, AB, Canada
Abstracts

P058
THE CHARACTERISTICS OF KIR2DL1 ALLELES POLYMORPHISM AND RECOGNITION HLA-C LIGAND IN THE CHINESE HAN POPULATION
Jun He, Miao Wang, Xiaojing Bao, Jiang Zhang. The First Affiliated Hospital of Soochow University, Suzhou, China

P059
META ANALYSIS OF SEQUENCE-BASED HLA TYPING APPROACHES
Szilveszter Juhos, Krisztina Rigo, Gyorgy Horvath, Tim Hague. Omixon Biocomputing Ltd, Budapest, Hungary

P060
HLA-B*52 HAPLOTYPIC DISTRIBUTION IN A BRAZILIAN SAMPLE
Bruno Z. Piovezan¹, Maria Elisa H. Moraes¹, Margareth A. Torres¹, Matilde Romero¹, Marcia Romero¹, Núbia Caroline C. Almeida¹, Kennie Amazones¹. ¹JRM Investigações Imunológicas, Rio de Janeiro, Brazil; ²LIG Laboratório de Imunogenética, São Paulo, Brazil; ³Fundação Amaral Carvalho, Jau, Brazil; ⁴Fundação HEMOPA, Pará, Brazil; ⁵Fundação HEMOPA, Belém, Brazil

P061
PROMOTER METHYLATION CAN AFFECT THE ANTIGEN AND mRNA EXPRESSION OF KIR3DL1
Sudan Tao, Yanmin He, Yanling Ying, Ji He, Faming Zhu, Hangjun Lv. Blood Center of Zhejiang Province, Hangzhou, China

P062
ALLELIC AND HAPLOTYPIC FREQUENCIES OF THE HLA-A, -B, -C, -DRB1 AND -DQB1 GENES IN POLYTRANSFUSED PATIENTS IN ETHNICALLY DIVERSE POPULATIONS FROM BRAZIL
Camila Rodrigues, Luciana C. Macedo, Adriana V. Bruder, Fernanda C. Quintero, Ana M. Sell, Jeane EL Visentainer. Universidade Estadual de Maringá, Maringá, Brazil

C. Rodrigues: Grant/Research Support; Company/Organization; Immunogenetics Laboratory - UEM, FAPESP, CAPES, CNPq.

P063
IDENTIFICATION OF A NEW DQB1 AND DPB1 ALLELE WITH SBT AND GENE CLONING
Jinguo Wang¹, Carrera Kostur¹, Luz Stamm¹, Faisal Khan², Noureddine Berka². ¹Calgary Laboratory Services, Calgary, AB, Canada; ²Calgary Laboratory Services and Univ. of Calgary, Calgary, AB, Canada

P064
KIR mRNA EXPRESSION IN NATURAL KILLER CELLS AND PERIPHERAL BLOOD MONONUCLEAR CELLS ASSAYED BY QUANTITATIVE REAL-TIME PCR
Yao Yuan¹, Sharon D. Adams¹, David M. Dinauer², Christopher M. Rosenau², Marcela R. Uribe¹, Willy A. Flegel¹. ¹National Institutes of Health, Bethesda, MD; ²Thermo Fisher Scientific, Brown Deer, WI
Abstracts

P065
PCR-SSOP AMBIGUITIES POLICY IN LOW/MEDIUM HLA TYPING FOR BONE MARROW VOLUNTEER DONATION
Alessandro Pirri, José Samuel Silva, Sonia Maria Machado Da Costa, Maria Da Graça Bicalho. Federal University Of Parana, Curitiba, Brazil

P066
PLATFORM-INDEPENDENT SOFTWARE AND REAGENTS FOR QPCR-BASED MICROCHIMERISM ANALYSIS
Jeroen Adema1, Dick Roovers1, Nienke Westerink1, Erik Rozemuller1,2, Doug Bost2. 1GenDx, Utrecht, Netherlands; 2KimerDx BV, Utrecht, Netherlands

J. Adema: Employee; Company/Organization; GenDx. D. Roovers: Employee; Company/Organization; GenDx. N. Westerink: Employee; Company/Organization; GenDx. E. Rozemuller: Employee; Company/Organization; GenDx. KimerDx BV. Stock Shareholder; Company/Organization; GenDx. KimerDx BV. Stock Shareholder; Company/Organization; KimerDx BV.

P067
TWO NOVEL ALLELES HLA-A*02:433 AND HLA-A*02:434 IDENTIFIED IN SAUDI BONE MARROW DONORS USING SEQUENCE-BASED TYPING
Hana Fakhoury1, Dunia Jawdat2, Ahmed Alaskar2, Mohammed Aljumah2, Ali H. Hajeer4. 1King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; 2King Abdullah International Medical Research Center, National Guard Health Affairs, Riyadh, Saudi Arabia; 3King Abdullah International Medical Research Center, National Guard Health Affairs, Riyadh, Saudi Arabia; 4King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

P068
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATIONS WITH KILLER IMMUNOGLOBULIN-LIKE RECEPTOR GENOTYPE MATCHED DONORS HAVE REDUCED INCIDENCE OF GRAFT VERSUS HOST DISEASE WITH NO EFFECT ON THE RISK OF DISEASE RELAPSE
Rehan M. Faridi1, Taylor J. Kemp1, Poonam Dharmani-Khan4, Victor A. Lewis3, Noureddine Berka1, Jan Storek4, Faisal M. Khan1. 1The University of Calgary, Calgary, AB, Canada; 2Alberta Children’s Hospital, Calgary, AB, Canada; 3Alberta Children’s Hospital, Calgary, AB, Canada; 4Calgary Laboratory Services, Calgary, AB, Canada; 5The University of Calgary, Calgary, AB, Canada

P069
ANALYSIS OF THE NON INHERITED HLA MATERNAL ANTIGENS-NIMA, IN THE BACECU-MEXICAN ALTRUISTIC CORD BLOOD BANK
Carmen Alaez1,2, Hilario Flores-A1,2, Fernanda Perez2, Diego Sanchez2, Danaee Rodriguez2, Elizabeth Soliz2, David Garcia1, Miriam Valencia1, Clara Gorodezky1,2. 1InDRE, Secretary of Health, Mexico City, D.F., Mexico; 2Fundación Comparte Vida, A.C., Mexico City, D.F., Mexico
P070
THREE NEW ALLELES HLA-C*14:02:13, HLA-C*15:72, AND HLA-C*15:74 IN SAUDI BONE MARROW DONORS
Hana Fakhoury1, Dunia Jawdat2, Ahmed Alaskar2, Mohammed Aljumah3, Ali H. Hajeer4. 1King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; 2King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; 3King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; 4King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

P071
DESCRIPTION OF THREE NOVEL ALLELES HLA-DQB1*05:48, HLA-DQB1*06:126, AND HLA-DQB1*06:123 IN SAUDI STEM CELL DONORS
Hana Fakhoury1, Dunia Jawdat2, Ahmed Alaskar2, Mohammed Aljumah3, Ali H. Hajeer4. 1King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; 2King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; 3King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; 4King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

P072
TWO NOVEL ALLELES HLA-DRB1*11:150 AND HLA-DRB1*14:145 IDENTIFIED IN SAUDI INDIVIDUALS
Hana Fakhoury1, Dunia Jawdat2, Ahmed Alaskar2, Mohammed Aljumah3, Ali H. Hajeer4. 1King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; 2King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; 3King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; 4King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

P073
IMMUNOBIOLOGY OF HLA-G IN SIBLING RELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION
Uma Kanga1, Manish Mourya1, Tulika Seth2, Lalit Kumar3, Manoranjan Mahapatra2, Pravas Mishra2, Narinder Mehra1. 1All India Institute of Medical Science, Delhi, India; 2All India Institute of Medical Science, Delhi, India; 3All India Institute of Medical Science, Delhi, India

P074
IDENTIFICATION OF NOVEL HLA ALLELES IN HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS
Taba Kheradmand, Rebecca Upchurch, Brenda Issangya, Walter Herczyk, Susana R. Marino. University of Chicago Medicine, Chicago, IL

P075
VARIABLE ANTIGEN EXPRESSION ON PLATELETS: IMPLICATIONS FOR ANTIGEN-NEGATIVE PLATELET SELECTION
Justin Kreuter, Patti Duellman, Steven De Goey, Nicole Henderson, Laurie Voit, James Stubbs, Manish Gandhi. Mayo Clinic, Rochester, MN

J. Kreuter: Other (Identify); Company/Organization; Immucor. P. Duellman: Other (Identify); Company/Organization; Immucor. S. De Goey: Other (Identify); Company/Organization; Immucor.
Abstracts

P076
ASSESSMENT OF CELL FRACTION PURITY BY PCR ON SEQUENTIAL LINEAGE-SPECIFIC CELL SEPARATIONS FOR CHIMERISM MONITORING
Tatiana Lebedeva, Charlotte Cronin, Vil Sydara, Brigid Bonin, Kara McGee, Sue Aronovitz, Neng Yu. American Red Cross, Dedham, MA

P077
IMPROVED SBTENGINE BATCH ANALYSIS MODULE
Erik H. Rozemuller, Job Geerligs, Maarten T. Penning, Wietse Mulder. GenDx, Utrecht, Netherlands

P078
ASSESSMENT OF CLINICAL SIGNIFICANCE OF NOVEL ALLELES FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
Runying Tian, Elaine Hodges, Candace Young, Angelica DeOliveira, Wendy E. Wegner, Gansuvd Balgansuren, Dong-Feng Chen. Duke University Medical Center, Durham, NC

P079
IS DNA ISOLATED FROM FROZEN PLASMA A RELIABLE METHOD FOR rSSOP HLA TYPING?
Jerome Weidner, Sana Ramahi, Susana R. Marino. University of Chicago Medicine, Chicago, IL

P080
BIOLOGICAL SIGNIFICANCE OF HLA-G IN TYPE 1 DIABETES SUSCEPTIBILITY AMONG NORTH INDIANS
Manish Kumar Mourya, Nikhil Tandon, Abhishweta Saxena, Poonam Coshie, Narinder Mehra, Uma Kang. 1All India Institute of Medical Science, Delhi, India; 2All India Institute of Medical Science, Delhi, India; 3All India Institute of Medical Science, Delhi, India

P081
STUDY OF THE INFLUENCE OF N-3 FATTY ACIDS IN THE SYNTHESIS OF NITRIC OXIDE DURING PARACOCCIDIOIDOMYCOSIS.
Sheisa C. Sargi, Vinicius J. Navarini, Marcia MO Dalalio, Jesui V. Visentainer. Universidade Estadual de Maringa, Maringa, Brazil

P082
IMPLEMENTATION OF NEXT GENERATION SEQUENCING (NGS) TECHNOLOGY FOR HLA TESTING: KEY LESSONS LEARNED FROM A MULTI-CENTER ALPHA STUDY
Medhat Askar, Dawn Thomas, Deborah Ferriola, Jamie Duke, Curt Lind, Dimitri Monos. 1Cleveland Clinic, Cleveland, OH; 2CHOP, Philadelphia, PA; 3CHOP, Philadelphia, PA
M. Askar: Employee; Company/Organization; Cleveland Clinic.
Abstracts

P083
DETERMINATION OF THE CLINICAL USEFULNESS OF HLA NEUTRALIZATION PROFILES
Rico Buchli1, Arend Mulder2, Annette Jackson3, Anat R. Tambur4, René J. Duquesnoy5, Rebecca D. McAdams1, Alyson Morris1, Rick Eggers6, Georgina Lopez Padilla7, Daniel Zehnder1, David P. Lowe8, David C. Briggs9, Robert Higgins10, Frans H.J. Claas11, Mike Hogan12, William H. Hildebrand13. 1Pure Protein LLC, Oklahoma City, OK; 2Leiden University Medical Center, Leiden, Netherlands; 3Johns Hopkins University, Baltimore, MD; 4Feinberg School of Medicine, Northwestern University, Chicago, IL; 5University of Pittsburgh Medical Center, Pittsburgh, PA; 6gmsbiotech, Tucson, AZ; 7The University of Warwick, Coventry, United Kingdom; 8Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; 9NHSBT Birmingham, Birmingham, United Kingdom; 10University Hospitals of Coventry & Warwickshire NHS Trust, Coventry, United Kingdom; 11Leiden University Medical Center, Leiden, Netherlands; 12Oklahoma University Health Sciences Center, Oklahoma City, OK

P084
THE HLA PROTEIN CHIP - A HIGH PERFORMANCE MICROARRAY PLATFORM FOR ANTI-HLA ANTIBODY DETECTION UTILIZING SOLUBLE HLA
Rico Buchli1, Rick Eggers2, Georgina Lopez Padilla3, Arend Mulder4, Annette Jackson5, Anat R. Tambur6, Frans H.J. Claas7, William H. Hildebrand7, Mike Hogan2. 1Pure Protein LLC, Oklahoma City, OK; 2GMSBiotech, Tucson, AZ; 3Leiden University Medical Center, Leiden, Netherlands; 4Johns Hopkins University, Baltimore, MD; 5GMSBiotech, Tucson, AZ; 6Leiden University Medical Center, Leiden, Netherlands; 7Leiden University Medical Center, Leiden, Netherlands; 7Oklahoma University Health Sciences Center, Oklahoma City, OK

P085
RAPID METHOD TO ELIMINATE HIGH BACKGROUND ON LUMINEX-SINGLE ANTIGEN BEADS (L-SAB) IN SERA FROM PATIENTS WITH VENTRICULAR ASSIST DEVICES (VAD)
Ge Chen1, Flavia Sequeira2, Dolly Tyan1. 1Stanford, Palo Alto, CA; 2Stanford, Palo Alto, CA

P086
IMPROVED ION TORRENT SEQUENCING CHEMISTRY ENABLES RAPID TURN AROUND AND 600BP READS
David Dinauer1, Jennifer Bollmer1, Zhoutao Chen2, Carolyn Bialozynski1, Joel Shi1, Scott Conradson1. 1ThermoFisher Scientific, Brown Deer, WI; 2ThermoFisher Scientific, Carlsbad, CA

D. Dinauer: Employee; Company/Organization; ThermoFisher. Stock Shareholder; Company/Organization; ThermoFisher.
J. Bollmer: Employee; Company/Organization; ThermoFisher. Z. Chen: Employee; Company/Organization; ThermoFisher.
C. Bialozynski: Employee; Company/Organization; ThermoFisher. J. Shi: Employee; Company/Organization; ThermoFisher.
S. Conradson: Employee; Company/Organization; ThermoFisher. Stock Shareholder; Company/Organization; ThermoFisher.

P087
LIS ON A SHOESTRING
Nebila Abdulwahab, Patrick Adams, Nicholas R. DiPaola. The Ohio State University, Columbus, OH
Abstracts

P088
HLA TYPING VALIDATION BY NEXT GENERATION SEQUENCING (NGS)
Ketevan Gendzekhadze¹, Lan-Feng Cao¹, Nelson Wyatt¹, Jean Garcia-Gomez¹, Daniel Geraghty², David Senitzer¹. ¹City of Hope, Duarte, CA; ²Scisco Genetics, Seattle, WA

N. Wyatt: Employee; Company/Organization; Scisco Genetics. Stock Shareholder; Company/Organization; Scisco Genetics.
D. Geraghty: Employee; Company/Organization; Scisco Genetics. Stock Shareholder; Company/Organization; Scisco Genetics.

P089
IS THERE A LINK BETWEEN TRANSCRIPTION AND HLA IN CARDIAC TRANSPLANTATION?
Vincenzo Grimaldi¹, Concetta Schiano², Monica Rienzo³, Amelia Casamassimi³, Antonietta Picascia⁴, Cristiano Amarelli⁵, Ciro Maiello⁶, Claudio Napoli¹,²,³. ¹U.O.C. Division of Immunohematology, Transfusion Medicine and Transplant Immunology (SIMT), Regional Reference Laboratory of Transplant Immunology (LIT), Azienda Ospedaliera Universitaria (AOU). Second University of Naples, Naples, Italy; ²IRCCS, SDN Foundation, Naples, Italy; ³Department of Biochemistry, Biophysics and General Pathology. Second University of Naples, Naples, Italy; ⁴Monaldi Hospital, Naples, Italy

P090
NEXT-GENERATION SEQUENCING-BASED HLA TYPING OF SALIVA AND BLOOD SAMPLES FROM THE SAME DONORS PRODUCES CONCORDANT TYPING RESULTS
Szilveszter Juhos¹, György Horváth¹, Attila Bérces¹, Curt Lind², Dmitri Monos²,³, Mike Tayeb⁴, Rafal Iwasiow⁴. ¹Omixon Biocomputing Ltd., Budapest, Hungary; ²Children’s Hospital of Philadelphia, Philadelphia, PA; ³University of Pennsylvania, Philadelphia, PA; ⁴DNA Genotek Inc., Kanata, ON, Canada

P091
A COMPARATIVE STUDY OF HLA TYPING USING AN ILLUMINA MISEQ NGS SYSTEM
Hiroto Kojima¹, Shinji Suegami¹, Nami Ikeda¹, Yuki Miyazaki¹, Akiko Ishitani², Hiroo Saji¹. ¹HLA Foundation Laboratory, Kyoto, Japan; ²Nara Medical University School of Medicine, Nara, Japan

P092
PERFORMANCE EVALUATION OF HIGH RESOLUTION 11 LOCI HLA-TYPING PROTOTYPE ASSAY USING NGS TECHNOLOGY
Cassandra Jabara¹, Marc Domanus¹, Dae Hyun Kim², Shialan Ho², Jeroen Adema², Nienke Westerink², Natalia Marlowe¹. ¹Abbott Molecular, Des Plaines, IL; ²GenDx, Utrecht, Netherlands

P093
PRESENTATION OF ESX FAMILY PROTEINS BY CLASSICAL AND NON-CLASSICAL CLASS I HLA AFTER M. TUBERCULOSIS INFECTION
Curtis McMurtrey¹, Melanie Harriff², Lauren Liles¹, Wilfried Bardet¹, Danijela Mojsilovic¹, Ken Jackson¹, Fredda Schafer¹, Gwendolyn Swarbrick², Deborah Lewinsohn², David Lewinsohn², William Hildebrand¹. ¹University of Oklahoma HSC, Oklahoma City, OK; ²Oregon Health Science University, Portland, OR
P094
A FULL NGS WORKFLOW FOR REACHING THE ULTIMATE HLA TYPING RESOLUTION
Jeroen Adema, Michelle Bacelar, Raul Kooter, Frans Paul Ruzius, Erik H. Rozemuller, Maarten T. Penning, Loes van de Pasch, Nienke Westerink. GenDx, Utrecht, Netherlands

J. Adema: Employee; Company/Organization; GenDx. M. Bacelar: Employee; Company/Organization; GenDx. R. Kooter: Employee; Company/Organization; GenDx. F. Ruzius: Employee; Company/Organization; GenDx. E.H. Rozemuller: Employee; Company/Organization; GenDx. M.T. Penning: Employee; Company/Organization; GenDx. L. van de Pasch: Employee; Company/Organization; GenDx. N. Westerink: Employee; Company/Organization; GenDx.

P095
HYBRID READS, A QUALITY VALUE FOR HLA AMPLIFICATION: MEASURED WITH NGSengine
Raul Kooter, Maarten T. Penning, Wietse Mulder, Erik H. Rozemuller. GenDx, Utrecht, Netherlands

R. Kooter: Employee; Company/Organization; GenDx. M.T. Penning: Employee; Company/Organization; GenDx. W. Mulder: Employee; Company/Organization; GenDx. E.H. Rozemuller: Employee; Company/Organization; GenDx.

P096
EVALUATION OF ENZYMATIC LIBRARY PREPARATION FOR THE ILLUMINA MISEQ
Tracie Profaizer, Emily M. Coonrod, Julio Delgado, Attila Kumanovics. ARUP Institute for Clinical and Experimental Pathology, Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT

P097
ACCURATE HLA TYPING BY NGS USING THE IonTorrent PGM WITH A PLATFORM SPECIFIC DEVELOPED AND TESTED WORKFLOW
Laura Krol, Jeroen Adema, Raul Kooter, Frans Paul Ruzius, Erik H. Rozemuller, Loes van de Pasch, Nienke Westerink. GenDx, Utrecht, Netherlands

L. Krol: Employee; Company/Organization; GenDx. J. Adema: Employee; Company/Organization; GenDx. R. Kooter: Employee; Company/Organization; GenDx. F. Ruzius: Employee; Company/Organization; GenDx. E.H. Rozemuller: Employee; Company/Organization; GenDx. L. van de Pasch: Employee; Company/Organization; GenDx. N. Westerink: Employee; Company/Organization; GenDx.

P098
HLA TYPING USING ION TORRENT PGM AND LONG RANGE HLA GENE AMPLIFICATION PRIMERS: EVALUATION OF ISOTHERMAL AMPLIFICATION AND HI-Q CHEMISTRY
Katsuyuki Saito1, Karl Beutner1, David Berman1, Olivia Sanchez2, Zhoutao Chen2, Melvin Wei2, Takashi Shiina3, Hidetoshi Inoko3, Jar-How Lee1. 1Transplant Diagnostics/Thermo Fisher, Canoga Park, CA; 2Thermo Fisher Scientific, Carlsbad, CA; 3Tokai University School of Medicine, Kanagawa, Japan

Abstracts

P099
A SINGLE CENTER COMPARISON OF HIGH-RESOLUTION HLA TYPING BY NEXT-GENERATION VERSUS SANGER SEQUENCING
Eric T. Weimer, John L. Schmitz. UNC - Chapel Hill, Chapel Hill, NC

P100
LONG RANGE NGS HLA TYPING IS ACCURATE IN THE IDENTIFICATION OF COMMON, RARE, AND NOVEL ALLELES
Yuxin Yin1, James H. Lan1,2, Elaine F. Reed4, Qiuheng Zhang1. 1UCLA Immunogenetics Center, Los Angeles, CA; 2University of British Columbia, Vancouver, BC, Canada

P101
DQB1*03:19 ASSOCIATION WITH DRB1 AND DQA1 IN NORTH CAROLINA POPULATION
Gansuvd Balgansuren, Karine Lopes, Adella Clark, Linda Peel, Candace Young, Angelica Deoliveira, Wendy Wegner, Dongfeng Chen. Duke University, Durham, NC

P102
GESTATIONAL DIABETES MELLITUS TRANSCRIPTOME ANALYSIS REVEALS INDUCTION OF GENES RELATED TO THE MAJOR HISTOCOMPATIBILITY COMPLEX
Eduardo A. Donadi, Natalia B. Cezar, Adriane F. Evangelista, Danilo J. Xavier, Amanda F. Assis, Thais C. Arns, Maria Cristina Foss-Freitas, Milton C. Foss, Elza T. Sakamoto-Hojo, Geraldo A. Passos. FMRP-USP, Ribeirao Preto, Brazil

P103
HIGH RESOLUTION HLA ALLELE FREQUENCIES OF STEM CELL DONORS IN MEXICO. GENETIC DIVERSITY AND ITS RELEVANCE TO IMPROVE UNRELATED DONOR SEARCHES
Hilario Flores-A1,2, Carmen Alaez1,2, Diego Sanchez2, Andrea Munguia1, Araceli Rodriguez1, David Garcia1, Clara Gorodezky1,2. 1InDRE, Secretary of Health, Mexico City, D.F., Mexico; 2Fundación Comparte Vida, A.C., Mexico City, D.F., Mexico

P104
SPECTRUM OF HLA ASSOCIATIONS WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN MEXICAN PATIENTS
Clara Gorodezky1,2, Hilario Flores-A1,2, Carmen Alaez1,2, Diego Sanchez2, Andrea Munguia1, Araceli Rodriguez1, David Garcia1, Miriam Valencia1, 1InDRE, Secretary of Health, Mexico City, D.F., Mexico; 2Fundación Comparte Vida, A.C., Mexico City, D.F., Mexico
P105
ALLELE-, HAPLOTYPE- AND GENOTYPE-LEVEL ASSOCIATIONS WITH CROHN’S DISEASE IN JEWISH AND NON-JEWISH EUROPEAN AMERICANS

Steven J. Mack1, Anna Lisa Fear1, Franziska Cohen1, Katrina A. Eaton1, Sherry K. Hawbecker1, Fernanda Ribas Goodridge1, Derek Pappas1, Jill A. Hollenbach1, Dermot P. B. McGovern1, Jerome I. Rotter1, Kent D. Taylor1, Elizabeth A. Trachtenberg2, Henry A. Erlich1. 1Children’s Hospital Oakland Research Institute, Oakland, CA; 2Cedars Sinai Medical Center, Los Angeles, CA; 3Los Angeles Biomedical Research Institute, Harbor-UCLA, Torrance, CA; 4Stanford University, Oakland, CA

P106
SMALL POPULATION SIZES LEAD TO LINKAGE DISEQUILIBRIUM OVERESTIMATES

Steven J. Mack1, Wolfgang Helmberg2, Ana M. Valdes3, Henry A. Erlich1, Janelle A. Noble1. 1Children’s Hospital Oakland Research Institute, Oakland, CA; 2Medical University of Graz, Graz, Austria; 3University of Nottingham, Nottingham, United Kingdom

P107
GENOMIC DIVERSITY OF HLA GENES AND HAPLOTYPES IN PUNJABI KHATRI POPULATION FROM INDIA

Abhishweta Saxena, Uma Kanga, Poonam Coshic, Manish Maurya, Narinder Mehra. All India Institute of Medical Sciences, Delhi, Delhi, India

P108
KIR–HLA LIGAND GENOTYPIC INTERACTION AND SUSCEPTIBILITY TO INFLAMMATORY BOWEL DISEASE

Elizabeth A. Trachtenberg1, Julia B. M. Udell1, Kazutoyo Oseegawa1, Martha B. Ladner1, David A. Noonan1, Dermot P. B. McGovern1, Jerome I. Rotter1, Kent D. Taylor1, Henry A. Erlich1. 1Stanford University, Palo Alto, CA; 2Cedars-Sinai Medical Center, Los Angeles, CA; 3Los Angeles Biomedical Research Institute, Harbor-UCLA, Torrance, CA; 4Children’s Hospital Oakland Research Institute, Oakland, CA

P109
CYTOKINES GENES AND AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE IN A BRAZILIAN POPULATION.

Everton F. Alves, Sueli Donizete Borelli, Luiza T. Tsuneto. State University of Maringá, Maringá, Brazil

P110
KIR GENES AND HLA LIGANDS IN THE PATHOGENESIS OF LEPROSY IN A HYPERENDEMIC POPULATION OF SOUTHERN BRAZIL.

Luciana R. Jardulí1, Hugo V. Alves1, Elaine V. C. Marcos1, Fabiana C. Souza2, Ana C. Pereira2, Marcelo T. Mira3, Milton O. Moraes4, Jeane EL Visentainer5. 1Universidade Estadual de Maringá, Maringá, Brazil; 2Instituto Lauro de Souza Lima, Bauru, Brazil; 3Pontificia Universidad Católica do Paraná, Curitiba, Brazil; 4FIOCRUZ, Rio de Janeiro, Brazil
Abstracts

P111
DISTRIBUTION OF CLASS I AND II HLA HAPLOTYPES IN A MIXED POPULATION FROM SOUTHERN BRAZIL.
Pamela G. Reis, Ana M. Sell, Ana C. Bettoni, Christiane M. Ayo, Giaretta A. Moraes, Karina M. Sakita, Ricardo A. Moliterno, Jeane EL Visentainer. Universidade Estadual de Maringa, Maringa, Brazil

P112
COMBATING CROSS-REACTIVITY IN HLA-B27 DETECTION BY FLOW CYTOMETRY
Laurie Voit, Crystal Keso, Lisa Hallaway, Justin D. Kreuter, Manish J. Gandhi. Mayo Clinic, Rochester, MN

P113
HLA HIGH RESOLUTION GENOTYPING USING 454 NGS AND GS GTYPE HLA ASSAY
Fumiko Yamamoto1, Cherie L. Holcomb2, Damian Goodridge3, Mathew W. Anderson4, Henry A. Erlich5, Dolly B. Tyan1, Marcelo A. Fernández-Viña1, 2Stanford University, Stanford Blood Center, Palo Alto, CA; 3Roche Molecular Systems, Pleasanton, CA; 4Conexio Genomics Pty Ltd, Fremantle Western Australia, Australia; 5BloodCenter of Wisconsin, Milwaukee, WI; 6Children’s Hospital Oakland Research Institute, Oakland, CA

P114
CHANGE OF THE PATIENT'S ANTI HLA ANTIBODY PROFILE BETWEEN INITIAL AND FINAL WORK-UP
Fadi Al Zayer1, Hassan Al Eid2, Amal AlGharably3, Amro Adnan4, Arlene Santos1, Moheeb Al Awwami1. 1King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; 2King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

P115
PRIMARY GRAFT DYSFUNCTION AFTER 0 MM KIDNEY TRANSPLANTATION SECONDARY TO ACUTE CELL MEDIATED REJECTION
Medhat Askar1, Gabriella Diaz2, Nisreen ElFadaway3, Lynne Klingman1, Dawn Thomas1, Andres Chiesa-Vottero4, Stuart Flechner5, Emilio Poggio5. 1Cleveland Clinic, Cleveland, OH; 2Hospital Durand, Buenos Aires, Argentina; 3Hospital Durand, Buenos Aires, Argentina; 4Cleveland Clinic, Cleveland, OH; 5Cleveland Clinic, Cleveland, OH

P116
T CELL POSITIVE AND B CELL NEGATIVE FCXM WITH PRONASE TREATED DONOR CELLS OBSERVED IN AN HIV INFECTED PATIENT
Gansuvd Balgansuren, Karine Lopes, Dongfeng Chen. Duke University, Durham, NC

P117
MASKING OF HLA IGG ANTIBODIES BY HLA IGM ANTIBODIES IN SINGLE ANTIGEN BEAD TESTING
Jennifer R. Baye, Maurine Davidson, David Maurer. University of Minnesota Medical Center - Fairview, Minneapolis, MN
Abstracts

P118
HEART TRANSPLANT AFTER ANTIBODY REDUCTION WITH BORTEZOMIB AND PLASMAPHERESIS IN A HIGHLY SENSITIZED PATIENT
Monika Gill1, Tim Humlicek1, Barbara Pisani1, Jose Mendez1, Maria Oppermann1, Michele Prod1, Siva Kanangat2. 1Rush University Medical Center, Chicago, IL; 2Rush University Medical Center, Chicago, IL

P119
A POSITIVE FLOW CROSSMATCH WHEN THE VIRTUAL CROSSMATCH WAS PREDICTED TO BE NEGATIVE....HIDDEN DONOR SPECIFIC ANTIBODY?
Walter Herczyk, Tenisha West, James Meade, Xiaohua Tian, Susana R. Marino. University of Chicago Medicine, Chicago, IL

P120
SIMULTANEOUS POLYOMA VIRUS (BKV) NEPHROPATHY, C4d POSITIVE ANTIBODY MEDIATED REJECTION (AMR) IN A RENAL TRANSPLANT CASE
Siva Kanangat, Maria Oppermann, Michele Prod, Ina Kurbegovic-Skaljic, SYLVIA PIGGOTT, Erin Christian, Nadia Parmakova, David Cimbaluk, Samuel Saltzberg, Steven Jensik, Edward Hollinger. Rush University Medical Center, Chicago, IL

P121
HIGH NONSPECIFIC AT1R REACTION IN A NON-SENSITIZED KIDNEY RECIPIENT
Mia Kost, John C. Magee, David B. Kershaw, Milagros D. Samaniego-Picota, Timothy C. Williams, Daniel S. Ramon. University of Michigan, Ann Arbor, MI

P122
DR7 PEDIATRIC HEART TRANSPLANT PATIENTS CAN HAVE ANTIBODIES REACTIVE TO DR4, 7 AND 9 SINGLE ANTIGEN BEADS THAT ARE NON-REACTIVE TO CELLS
Chantale Lacelle1, Bhavna Lavingia2, Bibhuti B. Das3. 1University of Texas Southwestern Medical Center, Dallas, TX; 2University of Texas Southwestern Medical Center, Dallas, TX; 3University of Texas Southwestern Medical Center, Dallas, TX

P123
GRAFT REJECTION IN A KIDNEY TRANSPLANT RECIPIENT WITH NEGATIVE CROSSMATCHES AND A SINGLE HLA-DP DONOR SPECIFIC ANTIBODY
Nathan A. Lemp1, James C. Cicciarelli1, Noriyuki Kasahara1, Michael Koss1,2, Don Vu1,4, Robert Naraghi1,4, Tariq Shah1,4, 1Viracor-IBT Laboratories, Los Angeles, CA; 2USC Keck School of Medicine, Los Angeles, CA; 3St. Vincent Medical Center, Los Angeles, CA; 4Transplant Research Institute, Los Angeles, CA
Abstracts

P124
PREDICTION OF NEGATIVE FLOW CYTOMETRY CROSS MATCH BASED ON ALLELE/HLA EPITOPE ANALYSIS: A CASE REPORT.

Allen J. Norin, Erin H. Chang, Mary Mondragon-Escopizo, David Hochman. SUNY Downstate Medical Center, Brooklyn, NY

A.J. Norin: Speaker's Bureau; Company/Organization; Immucor-Lifecodes. Scientific/Medical Advisor; Company/Organization; ICON CL.

P125
CASE STUDY: SUCCESSFUL TRANSPLANTATION OF SEPARATED PORTIONS OF A HORSESHOE KIDNEY

Gareth Page. Guy's Hospital, London, United Kingdom

P126
A CASE STUDY: ACUTE HUMORAL REJECTION DUE TO ANTI-HLA DP ANTIBODIES IN A RENAL TRANSPLANT RECIPIENT

Ankita Patel1, David H. Lee2, Sarah King2, Kristina Pinardo2, Sara Shepard2, Carol Pancoska2, Gitana Bradauskaite1, Stalin Campos3. 1Albert Einstein Medical Center, Philadelphia, PA; 2Albert Einstein Medical Center, Philadelphia, PA; 3Albert Einstein Medical Center, Philadelphia, PA

P127
TO TRANSPLANT OR NOT TO TRANSPLANT ACROSS A STRONGLY POSITIVE CROSSMATCH?

John Skibby, Ellen Klohe. Inland Northwest Blood Center, Spokane, WA

P128
LOW MFI DP DONOR SPECIFIC ANTIBODY PRODUCES UNEXPECTED WEAK POSITIVE FLOW B CELL CROSSMATCH

Teri-Lynn Steeves1, Christine Ribic1. 1Hamilton Health Sciences, Hamilton, ON, Canada; 2St Josephs Healthcare Hamilton, Hamilton, ON, Canada

P129
RECYCLE WHAT?

Kirsten Tronsgard, Bobbi Lynn Goudreau, Patricia Campbell, Luis Hidalgo. Universtiy of Alberta Hospital, Edmonton, AB, Canada

P130
CONFIRMATION OF AN ALLELE DROPOUT DEPENDANT ON DNA SOURCE

Adam Schoen, Nebila M. Abdulwahab, Nicholas Dipaola. The Ohio State University Wexner Medical Center, Columbus, OH
Abstracts

P131
PLATELET SUPPORT FOLLOWING HAPLOIDENTICAL STEM CELL TRANSPLANT: BLURRED LINES BETWEEN SELF AND NONSELF
Paula Arnold, Sheila Shurtleff, E. Victoria Turner. St. Jude Children’s Research Hospital, Memphis, TN

P132
AUTOLOGOUS STEM CELL TRANSPLANT FOLLOWING AN ORTHOTOPIC HEART TRANSPLANT AND CYTOXAN/BORTEZOMIDE/DEXAMETHASONE THERAPY FOR AMYLOIDOSIS WITH IMPROVEMENT OF KIDNEY FUNCTION
Fleur M. Aung. The University of Texas MD Anderson Cancer Center, Houston, TX

P133
RARE ALLELES IN ALLOGENEIC DONORS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION
Vincenzo Grimaldi1, Antonietta Picascia1, Amelia Casamassimi2, Claudio Napoli1,2. 1U.O.C. Division of Immunohematology, Transfusion Medicine and Transplant Immunology (SIMT), Regional Reference Laboratory of Transplant Immunology (LIT), Azienda Universitaria Policlinico (AOU), Second University of Naples, Naples, Italy; 2Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Naples, Italy
Abstracts

Late Breaking Posters

LBP01
DIFFERENT STROKES FOR DIFFERENT FOLKS: CONCORDANCE AND DISCORDANCE IN ANTI-HLA ANTIBODY TESTING
Moshe Israeli1, Marilyn S. Pollack2, Carley A. E. Shaut1, Anne Halpin4, Nicholas R. DiPaola3, Danny Youngs6, Susan L. Saidman7. 1Leiden University Medical Center, Leiden, Netherlands; 2University of Texas Health Science Center, San Antonio, TX; 3Oregon Health & Science University, Portland, OR; 4University of Alberta Hospital, Edmonton, AB, Canada; 5The Ohio State University, Columbus, OH; 6Puget Sound Blood Center, Seattle, WA; 7Massachusetts General Hospital and Harvard Medical School, Boston, MA

LBP02
AGE DEPENDENT HLA PROFILES IN A WORLD OF POPULATION MIGRATION: IMPACT ON HEMATOPOIETIC CELL DONOR RECRUITMENT AND AVAILABILITY
Moshe Israeli1, Machteld Oudshoorn1, Geert W. Haasnoot1, Tirza Klein2, Bracha Zisser1, Gideon Bach1, Frans H. J. Claas1. 1Leiden University Medical Center, Leiden, Netherlands; 2Rabin Medical Center, Petach-Tikva, Israel; 3Ezer-Minzion Bone Marrow Donor Registry, Petach-Tikva, Israel; 4Bedmavich-Chayi Public Cord Blood Bank, Jerusalem, Israel

LBP03
ALLOGENEIC-DRIVEN BENEFIT OF HUMAN CARDIAC-DERIVED STEM/PROGENITOR CELLS
Hocine Rachid, Hocine, Laura Laudon, Noémie Dam, Wahid Boukouaci, Dominique Charron, Reem Al-Daccak. Immunology, INSERM, Hôpital Saint Louis, IUH, Paris, France

LBP04
APPLICATION OF SINGLE MOLECULE REAL-TIME (SMRT) SEQUENCING TECHNOLOGY FOR THE FIELD 4 LEVEL GENOTYPING OF CLASSICAL HLA LOCI
Shingo Suzuki1, Brett N. Bowman2, Yuki Ozaki1, Shigeki Mitsunaga1, Hidetoshi Inoko1, Swati Ranade2, Takashi Shiina1. 1Tokai University School of Medicine, Kanagawa, Japan; 2Pacific Biosciences, Menlo Park, CA

LBP05
B CELL POSITIVE FLOWCYTOMETRY CROSS MATCH DUE TO DONOR SPECIFIC ANTIBODIES OF IgM ISOTYPE
Andrew L. Lobashevsky, Kevin M. Rosner, Melinda A. Kincade, Nancy G. Higgins. Indiana University Health, Methodist Hospital, Histocompatibility laboratory, Indianapolis, IN

LBP06
HLA-C ANTIBODY: HOW STRONG IS UNACCEPTABLE? DEFINING HLA-C ANTIBODY CUT-OFF AT ONE TRANSPLANT CENTER
Jessica Gatulis, Neng Yu, Jennifer Brissette, Gillian Lennon. Umass Memorial Medical Center, Worcester, MA
LBP07
EVALUATION OF MULTIPLEXING STRATEGIES FOR HLA GENOTYPING USING PACBIO SEQUENCING TECHNOLOGIES
Swati Ranade1, Kevin Eng2, John Harding1, Erik H. Rozemuller1, Nienke Westerink1, Maarten T. Penning2. 1Pacific Biosciences, Menlo Park, CA; 2GenDx, Menlo Park, CA; 3GenDx, Utrecht, Netherlands

LBP08
PLASMA TRANSFUSION/EXCHANGES MAY RESULT IN ACQUIRED PASSIVE DONOR SPECIFIC HLA ANTIBODY (DSA) IN CARDIAC TRANSPANTED PATIENTS
Raffaella Lopa1, Yu Bai2, Chengyu Wu2, Rhonda Hobbs1, Susan Rossman3, Beth Hartwell1, Cynthia Adams3, Leonida Legal-Stockwell1, Thuydung Tu2, Siram Nathan1, Pranav Loyalka1, Igor Gregoric2, Biswajit Kar1, John Bynon1, Min Ling1. 1UT Medical School at Houston/Memorial Hermann Hospital, Houston, TX; 2UT Medical School at Houston, Houston, TX; 3Gulf Coast Regional Blood Center, Houston, TX; 4UT Medical School at Houston, Houston, TX

LBP09
CASE STUDY: TREATMENT AND MONITORING FOR HYPER-ACUTE REJECTION OF A TRANSPANTED HEART
Min Ling1, Christina Paruthi2, Yu Bai2, Kimberly Klein1, Siram Nathan2, Nanish Patel2, Pranav Loyalka1, Min Ling1, Maximilian Buja1, Biswajit Kar1, Igor Gregoric2. 1UT Medical School at Houston/Memorial Hermann Hospital, Houston, TX; 2UT Medical School at Houston, Houston, TX; 3UT Medical School at Houston/Memorial Hermann Hospital, Houston, TX

LBP10
CO-EVOLUTION OF KIR AND HLA CLASS I IN A SOUTHERN AFRICAN HUNTER-GATHERER POPULATION
Hugo Hilton1, Paul Norman2, Neda Nemat-Gorgani2, Ana Goyos2, Christopher Gignoux1, Joanna Mountain1, Brenna Henn1, Lisbeth Guethlein2, Peter Parham1. 1Stanford University, Stanford, CA; 2Stanford University, Stanford, CA; 3UCSF, San Francisco, CA; 423 & Me, Mountain View, CA; 5Stony Brook University, Stony Brook, NY

LBP11
THE TEST OF TIME. A MULTICENTER EVALUATION OF THE RAPID OPTIMIZED SINGLE ANTIGEN BEAD (ROB) PROTOCOL FOR LABSCREEN.
Robert Liwski1, Patricia Campbell2, Adriana Colovai3, Deborah Crowe1, Anne Halpin2, Luis Hidalgo2, Ronald Kerman3, Peter Jindra4, Dong Li5, John Lutz3, Cathi Murphey4, Peter Nickerson2, Denise Pochinco4, Sandra Rosen-Bronson5, Olga Timofeeva4, Paul Warner19, Adriana Zevei1. 1Dalhousie University, Halifax, NS, Canada; 2University of Alberta, Edmonton, AB, Canada; 3Montefiore-Einstein Transplant Center, Bronx, NY; 4Dialysis Clinic Inc. (DCI) Laboratory, Nashville, TN; 5Baylor College of Medicine, Houston, TX; 6Medstar Georgetown University Hospital, Washington, DC; 7University of Pittsburgh Medical Center, Pittsburgh, PA; 8Southwest Immunodiagnostics, Inc., San Antonio, TX; 9University of Manitoba, Winnipeg, MB, Canada; 10Puget Sound Blood Center, Seattle, WA
Abstracts

LBP12
A COMPARISON OF DECEASED DONOR TYPING STRATEGIES ELICITED BY A NOVEL HLA-DPB1 ALLELE
Nathan A. Lemp1, Suhad Musa1, Jan Chew1, Jean Garcia-Gomez2, David Senitzer2, Noriyuki Kasahara1, James C. Cicciarelli1. 1Viracor-IBT Laboratories, Los Angeles, CA; 2City of Hope, Duarte, CA

LBP13
HLA MUTATIONS OBSERVED IN EBV-TRANSFORMED AND EXPANDED B-LYMPHOBLASTOID CELL LINES (BLCLS)
Elizabeth Beduhn1, Ana Lazaro2, Tatiana Lebedeva1, Elaine Reed1, Marcelo Fernandez-Vina1, Lindsay Carpenter1, Jen Poate1, Dan Scheller1, Gail Flickinger1. 1National Marrow Donor Program, Minneapolis, MN; 2Georgetown University, Washington, DC; 1American Red Cross Northeast Division, Dedham, MA; 1UCLA, Los Angeles, CA; 1Stanford School of Medicine, Palo Alto, CA

LBP14
TWO KIDNEY RECIPIENTS WITH GOOD FUNCTION AND DONOR SPECIFIC ANTIBODIES POSITIVE FOR C1Q AND IGG4 SUBCLASS
James C. Cicciarelli1, Nathan A. Lemp1, Noriyuki Kasahara1, Kevin Burns2, Bruce Williams3, Sheila Bloom1, Rolando Montes1, Bennie Pitpitan1, Barry Brown1, Steven Steinberg1. 1Viracor-IBT Laboratories, Los Angeles, CA; 2BloodSource, Sacramento, CA; 3Sharp Memorial Hospital, San Diego, CA

LBP15
THE CHANCE OF FINDING A FULLY MATCHED RELATED DONOR IN SAUDI ARABIA: CAN IT BE HELPFUL TO DETERMINE THE BEST ALTERNATIVE DONOR SOURCE?
rabab A. alattas1, Hassan ALHarbi2, Sameera Afghani1. 1King Fahad Specialist Hospital, Dammam, Saudi Arabia; 2HIL, DPLM, King Fahad Specialist Hospital, Dammam, Saudi Arabia; 1Oncology center, King Fahad Specialist Hospital, Dammam, Saudi Arabia

LBP16
THE DILEMMA OF DQ HLA- ANTIBODIES
Rabab A. Alattas, Dalal AlAbduladheem, Adel Shawhati, Ricardo Lopez, Saber AlZahrani, Abdulnaser Abadi, Nasreen Hasan, Khalid Akkari. King Fahad Specialist Hospital, Dammam, Saudi Arabia

LBP17
A SCIENTIFIC MYTH: THERE IS MORE HLA CLASS I ON B CELLS THAN ON T CELLS
Flavia Sequeira, Dolly Tyan, Ge Chen. Stanford, Palo Alto, CA
Abstracts

LBP18
HLA-PEPTIDE BINDING ANALYSIS BY THE CELL-SURFACE EXPRESSINO ASSAY
Hiroko Miyadera1,2, Toshio Kitamura3, Masashi Mizokami1, Katsushi Tokunaga2. 1National Center for Global Health and Medicine, Chiba, Japan; 2Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; 3The Institute of Medical Sciences, The University of Tokyo, Tokyo, Japan

LBP19
EXTENDED COVERAGE BY NEXT GENERATION SEQUENCING METHODS REFINES THE CHARACTERIZATION OF THE COMMON AND WELL DOCUMENTED HLA ALLELES

LBP20
RELEVANCE OF STRONG POSITIVE DONOR SPECIFIC ANTIBODIES AND FLOW CROSSMATCH WHILE C1q TEST NEGATIVE IN RENAL TRANSPLANTATION
Ashraf Dada, Sr.1, Wael Habhab2, Najla Zabani2, Fakhr Eldein Elamein2, Ahmed Fahmy1, Alaa Al Sayed1, Nabila Al Baz1, Ahmad Bokhari1. 1King Faisal Specialist Hospital & Research Centre, Department of Pathology & Laboratory Medicine, Jeddah, Saudi Arabia; 2King Faisal Specialist Hospital & Research Centre, Department of Internal Medicine, Jeddah, Saudi Arabia; 3King Faisal Specialist Hospital & Research Centre, Department of Surgery, Jeddah, Saudi Arabia

LBP21
LABORATORY INFORMATION SYSTEM IMPLEMENTATION AND INTEGRATION: ACHIEVING A FULLY FUNCTIONAL SYSTEM
Yelena Kleyman-Smith, Thomas Peterson, Jagadish Chaparala, Kathryn Daavettila, Timothy Williams, Daniel S. Ramon. Histocompatibility Laboratory. Pathology, Universtity of Michigan Health System, Ann Arbor, MI

LBP22
STRONG DONOR SPECIFIC ANTI-HLA DR53 ANTIBODY DETECTED BY SINGLE-ANTIGEN BEADS SHOULD NOT ALWAYS PREVENT TRANSPLANTATION
Elizabeth Portwood, Paul A. Brailey, Matthew Blanton, Alin Girnita. Hoxworth Blood Center, Cincinnati, OH

LBP23
CLINICAL RELEVANCE OF CYTOKINE GENE POLYMORPHISM ON POST TRANSPLANT RENAL ALLOGRAFT SURVIVAL
Jamshaid A. Siddiqui, III1,2, Gurvinder Kaur1, Dipankar Bhowmik1, Sandeep Guleria2, Suresh C. Tiwari2, Narinder K. Mehra2. 1Jazan University, Jazan, Saudi Arabia; 2All India Institute of Medical Sciences, New Delhi, India; 3All India Institute of Medical Sciences, India, India
LBP24
MULTI-PARAMETER FLOW CYTOMETRY OF T-CELL SUBPOPULATIONS AND LINEAR MIXED EFFECTS MODEL TO CHARACTERIZE MULTIORGAN DYSFUNCTION SYNDROME AFTER MECHANICAL CIRCULATORY SUPPORT DEVICE
Yael Korin1,2, Nicholas Wisniewski1,2, Martin Cadeiras3, Joanna Schena1, Murray Kwon1,2, Tiffany Sidwell1,2, Fadi Kandarian1,2, Galyna Bondar1,4, Elaine Reed1,4, Mario Deng1,2, 1UCLA Immunogenetics Center, Department of Pathology and Laboratory Medicine, Los Angeles, CA; 2, David Geffen School of Medicine at UCLA, Los Angeles, CA., 3, Advanced Heart Failure Program, Division of Cardiology, Department of Medicine, Los Angeles, CA; 4David Geffen School of Medicine at UCLA, Los Angeles, CA; 5Advanced Heart Failure Program, Division of Cardiology, Department of Medicine, Los Angeles, CA; 6, David Geffen School of Medicine at UCLA, Los Angeles, CA; 7Division of Infectious Diseases, Department of Medicine, Los Angeles, CA; 8David Geffen School of Medicine at UCLA, Los Angeles, CA; 9Division of Cardiothoracic Surgery, Department of Surgery, Los Angeles, CA

LBP25
TYPE 1 DIABETES: AROUND THE WORLD WITH HLA
Janelle A. Noble1, Julie A. Lane1, Gunduz Ahmadov2, Yakoob Ahmedani2, Asher Fawwad4, Bedowra Zabeen1, Mark Atkinson6, Martin Silink1, Graham Ogle1. 1Children’s Hospital Oakland Research Institute, Oakland, CA; 2Endocrine Centre and Azerbaijan Medical University, Baku, Azerbaijan; 3Baqai Medical University, Karachi, Pakistan; 4Baqui Institute of Diabetology and Endocrinology, Karachi, Pakistan; 5Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders, Dhaka, Bangladesh; 6Diabetes Institute at University of Florida Health, Gainesville, FL; 7Children’s Hospital at Westmead, Sydney, Australia; 8Australian Diabetes Council, Sydney, Australia

LBP26
THE NIMA EFFECT IN CORD BLOOD TRANSPLANT (CBT): REAL OR A CONSEQUENCE OF BETTER HIGH RESOLUTION (HR) MATCHING IN THE NIMA MATCHED (NIMA+) GROUP?
Colleen Brady1, Vanja Paunic2, Mike Haagenson1, Annalisa Ruggeri1, Eliane Gluckman1, Vanderson Rocha1, Mary Eapen1, Martin Maiers2, Steven Spellman1, 1CIBMTR, Mineapolis, MN; 2NMDP, Mineapolis, MN; 3Eurocord, Hopital Saint Louis, Paris, France; 4Churchill Hospital, Oxford, United Kingdom; 5CIBMTR, Medical College of Wisconsin, Milwaukee, WI

LBP27
DECIPHERING STRONG AUTO AND ALLO HLA ANTIBODY REACTIVITIES POST ANGIOPLASTY FOR RENAL TRANSPLANT CANDIDATES
Jennifer Brissette, Neng Yu, Jessica Gatulis, Gillian Lennon. UMass Memorial Medical Center, Worcester, MA

LBP28
A ROLE FOR IFN-6 STIMULATED MONOCYTES IN ANTIBODY-MEDIATED DAMAGE BY C1Q+ DSA
MICHAEL PARKES1, CARMEN LEFAUCHEUR2, ALEX LOUPY3, PHIL HALLORAN1, LUIS Hidalgo1. 1UNIVERSITY OF ALBERTA, EDMONTON, AB, Canada; 2St Louis University Hospital, Paris, France; 3Université Paris Descartes, Paris, France
Abstracts

LBP29
TRANSPLANTATION OF SENSITIZED HEART PATIENTS
Liang Wan, Chet Patel, Joseph Rogers, Carmelo Milano, Wendy E. Hanshew, Dong-Feng Chen. Duke University Medical Center, Durham, NC

LBP30
THE SPECIFICITY OF HLA-DP ANTIBODIES ARE DEFINED BY TWO DIMORPHIC EPITOPES
Xiaohai Zhang, Jeffrey McNamara, David Gjertson, Michael Cecka, Elaine Reed. the UCLA Immunogenetics Center, Los Angeles, CA

LBP31
MOLECULAR MEASUREMENT OF T-HELPER SUBSET GENE TRANSCRIPTS IN PERIPHERAL BLOOD RAPIDLY AND ACCURATELY IDENTIFIES SUBSET VARIATIONS IN RELATION TO GRAFT STATUS
Phillip Ruiz, Emilio Margolles-Clark. University of Miami, Miami, FL

LBP32
FETAL MICROCHIMERISM IN DEVELOPING OF ACUTE GVHD AFTER HAPLOIDENTICAL BMT.
Ildar Barkhatov, Youri Serov, A. Shakirova, O. Smykova, L. Zubarovskaya, Boris Afanasyev. First Pavlov State Medical University of St.Petersburg, Saint Petersburg, Russian Federation

LBP33
DEFINING A CLINICALLY RELEVANT CUTOFF FOR THE IDENTIFICATION OF HLA ANTIBODIES USING THE SINGLE ANTIGEN BEAD ASSAY
Eric Salazar, Todd N. Eagar, Geoffrey A. Land. Houston Methodist Hospital, Houston, TX

LBP34
ANTI-HUMAN GLOBULIN (AHG) ENHANCED C1Q ASSAY IMPROVES DETECTION OF DONOR SPECIFIC HLA ANTIBODIES (DSA) IN HEART TRANSPLANT RECIPIENTS WITH ANTIBODY MEDIATED REJECTION.
Fengxia Ge¹, Lingzhi Li², Xiwei Tang¹, Eric Ho¹, Charles-Chuck Marboe¹, Rodica Vesilescu¹, Robert Liwski², Raphael A. Clynes¹. ¹Columbia University Medical Center, NEW YORK, NY; ²Dalhousie University, Halifax, NS, Canada
Abstracts

LBP35
STRENGTH OF DE NOVO HLA DONOR SPECIFIC ANTIBODY IS A STRONG PREDICTOR OR ITS C1Q BINDING CAPABILITY
Salim Ghandorah1, Jinguo Wang2, Amir Ahadzadeh1, Abdulnaser Alabadi3, Serdar Yilmaz2,4, Faisal Khan4,5, Noureddine Berka6,7.
1University of Calgary, Calgary, AB, Canada; 2Calgary Laboratory Services, Calgary, AB, Canada; 3Foothills Medical Center, Calgary, AB, Canada; 4Division of Transplantation, University of Calgary, Calgary, AB, Canada; 5Departments of Pathology & Laboratory Medicine, Calgary, AB, Canada; 6Department of Pathology and Laboratory Medicine, Calgary, AB, Canada

LBP36
MATCHING FOR SNP’S IN THE MHC GAMMA BLOCK REDUCES THE RISK OF GVHD AND INCREASES SURVIVAL RATES POST HSCT
Hayley M. Hogan, Karolina Dimovski, Damian M. Goodridge, David C. Sayer, Conexio, Wangara, Australia

LBP37
THE INCIDENCE OF AT1R ANTIBODY IN SOLID ORGAN TRANSPLANT AND CORRELATION WITH PRE-TRANSPLANT FACTORS
Mohammad I. Awaji1,2, Catherine L. Gebhart1, Sally J. Schumacher1. 1University of Nebraska Medical Center, Omaha, NE; 2King Fahad Specialist Hospital, Dammam, Saudi Arabia; 3Nebraska Medical Center, Omaha, NE
Hotel Floor Plans

PLAZA BUILDING CONCOURSE LEVEL
Exhibit Hall Floor Plans
Future Annual Meetings

41st Annual Meeting
September 28 – October 2, 2015
Savannah Convention Center
Savannah, GA

42nd Annual Meeting
September 26 – 30, 2016
Hyatt Regency St. Louis at the Arch
St. Louis, MO

43rd Annual Meeting
September 11 – 15, 2017
Hilton San Francisco Union Square
San Francisco, CA